Skip to main content
Erschienen in: Antimicrobial Resistance & Infection Control 1/2017

Open Access 01.12.2017 | Research

Genome sequencing and analysis of the first spontaneous Nanosilver resistant bacterium Proteus mirabilis strain SCDR1

verfasst von: Amr T. M. Saeb, Khalid A. Al-Rubeaan, Mohamed Abouelhoda, Manojkumar Selvaraju, Hamsa T. Tayeb

Erschienen in: Antimicrobial Resistance & Infection Control | Ausgabe 1/2017

Abstract

Background

P. mirabilis is a common uropathogenic bacterium that can cause major complications in patients with long-standing indwelling catheters or patients with urinary tract anomalies. In addition, P. mirabilis is a common cause of chronic osteomyelitis in Diabetic foot ulcer (DFU) patients. We isolated P. mirabilis SCDR1 from a Diabetic ulcer patient. We examined P. mirabilis SCDR1 levels of resistance against Nanosilver colloids, the commercial Nanosilver and silver containing bandages and commonly used antibiotics. We utilized next generation sequencing techniques (NGS), bioinformatics, phylogenetic analysis and pathogenomics in the characterization of the infectious pathogen.

Results

P. mirabilis SCDR1 was the first Nanosilver resistant isolate collected from a diabetic patient polyclonal infection. P. mirabilis SCDR1 showed high levels of resistance against Nanosilver colloids, Nanosilver chitosan composite and the commercially available Nanosilver and silver bandages. The P. mirabilis -SCDR1 genome size is 3,815,621 bp. with G + C content of 38.44%. P. mirabilis-SCDR1 genome contains a total of 3533 genes, 3414 coding DNA sequence genes, 11, 10, 18 rRNAs (5S, 16S, and 23S), and 76 tRNAs. Our isolate contains all the required pathogenicity and virulence factors to establish a successful infection. P. mirabilis SCDR1 isolate is a potential virulent pathogen that despite its original isolation site, the wound, can establish kidney infection and its associated complications. P. mirabilis SCDR1 contains several mechanisms for antibiotics and metals resistance, including, biofilm formation, swarming mobility, efflux systems, and enzymatic detoxification.

Conclusion

P. mirabilis SCDR1 is the first reported spontaneous Nanosilver resistant bacterial strain. P. mirabilis SCDR1 possesses several mechanisms that may lead to the observed Nanosilver resistance.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s13756-017-0277-x) contains supplementary material, which is available to authorized users.
Abkürzungen
16S rRNA
16S ribosomal RNA gene
AMRO
Antimicrobial Resistance based ontology
AROs
Antibiotic Resistance Ontology
BLASTn
Basic Local Alignment Search Tool nucleotide
bp
Base pair
DDT
1, 1, 1-Trichloro-2, 2-bis (4-chlorophenyl) ethane
DFU
Diabeticfoot ulcer
GC content
guanine-cytosine content
KFSHRC
King Faisal Specialist Hospital and Research Center
Mb
Mega base pairs
MDR
multidrug-resistant
MIC
Minimum Inhibitory Concentration
MRSA
methicillin-resistant Staphylococcus aureus
MRSE
methicillin -resistant Staphylococcus epidermidis
NGS
Next generation sequencing techniques
PATRIC
Pathosystems recourse Integration center
PPM
part per million
RGI
Resistance Gene Identifier
RND
Resistance-Nodulation- Division
SCDR
Strategic center for Diabetes research
tRNAs
Transfer ribonucleic acid
VRE
Vancomycin-resistant Enterococcus

Background

The production and utilization of nanosilver is one of the primary and still growing applications in the field of nanotechnology. Nanosilver is used as the essential antimicrobial ingredient in both clinical and environmental technologies. Nanosilver is utilized in the formulation of dental resin amalgams, medical device coatings, water filter antimicrobial coating, antimicrobial agents in air sanitizers, textiles, pillows, respirators, socks, wet wipes, detergents, soaps, shampoos, toothpastes, washing machines, bone cement, wound dressings, hospital beds and furniture to control infection and support anti-biofilm activity [18]. Nanosilver is known to exert inhibitory and bactericidal effects against many Gram-positive, Gram-negative and fungal pathogens [9]. Latest studies suggest that the use of nanosilver-containing wound dressings prevents or reduces microbial growth in wounds, and may improve the healing process [10]. Moreover, antibacterial nanosilver-containing wound dressing gels may be important for patients that are at risk of non-healing of diabetic foot wounds and traumatic/surgical wounds [11]. Increased usage of nanosilver in both medical and environmental products has generated concerns about the development of bacterial resistance against the antimicrobial ingredient. Bacterial resistance against metallic silver has been documented with several bacterial strains such as E. coli Enterobacter cloacae, Klebsiella pneumoniae and Salmonella typhimurium [12, 13]. However, information about bacterial resistance against Nanosilver is scarce. Only Gunawan et al., (2013) reported the occurrence of induced adaptation, of non-targeted environmental Bacillus species, to antimicrobial Nanosilver [14]. In this study, we report on a spontaneous nanosilver-resistant Proteus mirabilis isolate (“SCDR1”). Proteus mirabilis is a motile gram-negative bacterium that is characterized by its swarming behavior [15, 16]. P. mirabilis is a common uropathogen that can cause major complications. In addition, P. mirabilis can cause respiratory and wound infections, bacteremia, and other infections [1621]. In fact, P. mirabilis is a common cause of chronic osteomyelitis in Diabetic foot ulcer (DFU) patients along with Bacteroides fragilis, E coli, and Klebsiella pneumoniae [22]. Generally, P. mirabilis is responsible for 90% of genus Proteus infections, and can be considered as a community-acquired infection [23]. As a pathogen P. mirabilis acquires many virulence determinants that enable it to establish successful infections [2426]. A lot of information concerning antibiotic resistance is available for P. mirabilis [2735]. P. mirabilis is intrinsically resistant to tetracyclines and polymyxins. Moreover, multidrug-resistant (MDR) P. mirabilis strain resistance to β-lactams, aminoglycosides, fluoroquinolones, phenicols, streptothricin, tetracycline, and trimethoprim-sulfamethoxazole has been reported [36]. However, limited information about heavy metals, including silver, is available. In this study, we present the first report and genome sequence of the nanosilver resistant bacterium P. mirabilis strain SCDR1, isolated from diabetic foot ulcer (DFU) patient.

Methods

Bacterial isolate

Proteus mirabilis strain SCDR1 was isolated from a diabetic ulcer patient in the diabetic foot unit at the University Diabetes Center, King Saud University. P. mirabilis SCDR1 was the first nanosilver resistant isolate to be collected from a diabetic patient’s polyclonal infection. A Proper wound swab was obtained from the patient and was sent for further microbiological study and culture. Wounds needing debridement were debrided before swabbing the surface of the wound. The specimen was inoculated onto blood agar (BA; Oxoid, Basingstoke, UK) and MacConkey agar (Oxoid) and incubated at 37 °C for 24–48 h. The Vitek 2 system and its advanced expert system were used for microbial identification, antibiotic sensitivity testing, and the interpretation of results. ID GN cards were used to identify the bacterial isolate, and AST-N204 was used for the antimicrobial susceptibility testing of gram-negative rods. Manual disk diffusion and MIC method for AgNPs and antibiotic sensitivity testing were performed when required. Results were categorized according to EUCAST 2.0 VITEK 2 MIC breakpoints.

Preparation of colloidal and composite Nanosilver and commercial products for antimicrobial activity testing

Colloidal silver nanoparticles were prepared and characterized, and their concentration was determined as described by Saeb et al., 2014 [9]. Nanosilver chitosan composite preparations were made by chemical reduction method, as described by Latif et al., 2015 [37]. Moreover, the following commercially silver and nanosilver containing wound dressing bandages were used for antimicrobial activity testing: Silvercel non-adherent antimicrobial alginate Dressing (Acelity L.P. Inc., San Antonio, Texas, USA), Sorbsan Silver dressing made of Calcium alginate with silver (Aspen Medical Europe Ltd., Leicestershire, UK), ColActive® Plus Ag (Covalon Technologies Ltd., Mississauga, Ontario, Canada), exsalt®SD7 wound dressing (Exciton Technologies, Edmonton, Alberta, Canada), Puracol Plus AG+ Collagen Dressings with Silver (Medline, Mundelein, Illinois, USA) and ACTISORB™ silver antimicrobial wound dressing 220 (Acelity L.P. Inc., San Antonio, Texas, USA).

Antimicrobial susceptibility test

Antimicrobial activities were performed against the following strains: Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213, Proteus mirabilis ATCC 29906, Klebsiella pneumoniae ATCC 700603, E. coli ATCC 25922 and Enterobacter cloacae ATCC 29212.

Disk diffusion antimicrobial susceptibility testing

Disk diffusion antimicrobial susceptibility testing was performed as described by Matuschek et al. [38]. Briefly, Mueller–Hinton (MH) agar plates were inoculated with agar with an inoculum corresponding to a McFarland 0.5 turbidity with a sterile cotton swab to prepare bacterial lawns of the abovementioned bacterial test strains. Sterile discs were loaded with different concentrations (50–200 ppm) of colloidal silver nanoparticles solutions and the Nanosilver chitosan composite (composite concentration ranged from 0.1% and 0.01 M to 3.2% and 0.16 M from chitosan and Silver nitrate respectively) and then placed on Mueller–Hinton (MH) agar plates with bacterial lawns. Within 15 min of application of antimicrobial disks, the plates were inverted and incubated at 37C for 16 h. All experiments were done in aseptic conditions in a laminar air flow cabinet. After incubation, inhibition zones were read at the point where no apparent growth was detected. The inhibition zone diameters were measured to the nearest millimeter. Similarly, 5 mm desks from the commercially available bandages were prepared in aseptic conditions and tested for antimicrobial activity, as previously described.

Minimum bactericidal (MBC) and minimal inhibitory concertation (MIC) test

MBC and MIC testing were performed as described by Holla et al., [39]. Briefly, a dilution with 1 × 105 CFU/ml (equivalent to 0.5 McFarland) was used as an inoculum for MIC testing. Different volumes that contained a range of silver Nanoparticles (50–700 ppm) were delivered to 7.5 ml of Muller-Hinton (MH) broth, each inoculated with 0.2 ml of the bacterial suspensions. Within 15 min of application of silver nanoparticles, the tubes were incubated at 37C for 16 h in a shaker incubator at 200 rpm. We included a positive control (tubes containing inoculum and nutrient media without silver nanoparticles) and a negative control (tubes containing silver nanoparticles and nutrient media without inoculum).

Biofilm formation

In order to test the ability of P. mirabilis SCDR1 isolate to form biofilm, a culture was prepared by inoculation on Columbia agar, supplemented with 5% blood and incubated at 37 C° for 24 h. The culture was then used to prepare 0.5 McFarland standard bacterial suspension. Wells of sterile 96- well flat- bottomed plastic microplates were filled with 250 μL of the Brain-heart infusion broth. Negative control wells contained the broth only. Twenty μL of bacterial suspension were then added to each well. The plate was incubated at 37 C° for 24 h. Following the incubation, the content of each well was aspirated and washed three times with 300 μL of sterile distilled water. The remaining attached bacteria were fixed with 200 μL of methanol per well, and after 15 min the plates were emptied and left to dry air. After this, the plates were stained for 5 min with 160 μL per well of crystal violet used for gram stain. Excess stain was rinsed off by placing the microplates under running tap water. After the plates were air dried, the dye which was bound to the adherent cells was re-solubilized with 160 μL of 33% (v/v) glacial acetic acid per well. The optical density (OD) was measured at 570 nm [40].

Molecular genomics analysis

DNA purification, sequencing, bioinformatics and phylogenetic analysis

DNA isolation, purification, genome sequencing, bioinformatics and phylogenetic analysis were performed as described by Saeb et al., 2017 [41]. In addition, we used Mauve [42] and CoCoNUT [43] to generate the whole genome pairwise and multiple alignments of the draft P. mirabilis strain SCDR1 genome against selected reference genomes. Furthermore, we performed whole genome phylogeny based proteomic comparison among P. mirabilis SCDR1 isolate and other related Proteus mirabilis strains using Proteome Comparison service which is a protein sequence-based comparison using bi-directional BLASTP available at (https://​www.​patricbrc.​org/​app/​SeqComparison) [44].

Gene annotation and Pathogenomics analysis

P. mirabilis SCDR1 genome contigs were annotated using the Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP) available at NCBI (http://​www.​ncbi.​nlm.​nih.​gov/​). In addition, contigs were further annotated using the bacterial bioinformatics database and analysis resource (PATRIC) gene annotation service (https://​www.​patricbrc.​org/​app/​Annotation) [44]. The PathogenFinder 1.1 pathogenicity prediction program available at (https://​cge.​cbs.​dtu.​dk/​services/​PathogenFinder/​) was used to examine the nature of P. mirabilis SCDR1 as a human pathogen [45]. Virulence gene sequences and functions, corresponding to different major bacterial virulence factors of Proteus mirabilis were collected from GenBank and validated using virulence factors of the pathogenic bacteria database available at (http://​www.​mgc.​ac.​cn/​VFs/​) [46], the Victors virulence factors search program available at (http://​www.​phidias.​us/​victors/​) and the PATRIC_VF tool available at https://​www.​patricbrc.​org/​= [44].

Resistome analysis

P. mirabilis SCDR1 genome contigs were investigated manually for the presence of antibiotic resistance loci using the PGAAP and PATRIC gene annotation services. Antibiotic resistance loci were further investigated using specialized search tools and services, namely Antibiotic Resistance Gene Search available at (https://​www.​patricbrc.​org/​=) [44], Genome Feature Finder (antibiotic resistance) available at (https://​www.​patricbrc.​org/​=) [44], ARDB (Antibiotic Resistance Genes Database) available at (https://​ardb.​cbcb.​umd.​edu/​) [47],
CARD (The Comprehensive Antibiotic Resistance Database) available at (https://​card.​mcmaster.​ca/​) [48, 49], Specialty Gene Search available at (https://​www.​patricbrc.​org/​=) and ResFinder 2.1 available at (https://​cge.​cbs.​dtu.​dk/​/​services/​ResFinder/​) [50].
The heavy metal resistance gene search for P. mirabilis SCDR1 contigs were investigated using PGAAP and PATRIC gene annotation services, PATRIC Feature Finder searches tool and BacMet (antibacterial biocide and metal resistance genes database) available at (http://​bacmet.​biomedicine.​gu.​se/​) [44, 51].

Results

Initial identification and antimicrobial susceptibility test

The Vitek 2 system showed that our isolate belongs to the Proteus mirabilis species. Antibiotic sensitivity testing using Vitek 2 AST-N204 card showed that our isolate P. mirabilis SCDR1 is resistant to ampicillin, nitrofurantoin, and Trimethoprim/ Sulfamethoxazole. In addition, P. mirabilis SCDR1 was resistant to ethidium bromide, tetracycline, tigecycline, colistin, polymyxin B, rifamycin, doxycycline, vancomycin, fusidic acid, bacitracin, metronidazole, clarithromycin, erythromycin, oxacillin, clindamycin, trimethoprim, novobiocin, and minocycline. P. mirabilis SCDR1 was intermediate resistant against nalidixic acid, Imipenem, and Cefuroxime. Conversely, it was sensitive to chloramphenicol, amoxicillin/ clavulanic Acid, piperacillin/tazobactam, cefotaxime, ceftazidime, cefepime, cefaclor, cephalothin, ertapenem, meropenem, amikacin, gentamicin, ciprofloxacin, norfloxacin, tobramycin, streptomycin, and fosfomycin.
P. mirabilis SCDR1 isolate showed high resistance against colloidal and composite Nanosilver and metallic silver compared with other tested Gram positive and negative bacterial species. For instance, Table 1, shows the resistance of P. mirabilis SCDR1 against colloidal Nanosilver assessed by the disk diffusion method, in comparison with S. aureus ATCC 29213, P. aeruginosa ATCC 27853, E. coli ATCC 25922 and E. cloacae ATCC 29212. Generally, P. mirabilis SCDR1 showed high resistance (0.0 cm), while K. pneumoniae showed the highest sensitivity (1.5–1.9 cm) against all tested silver nanoparticle concentrations (50–200 ppm). S. aureus also showed high sensitivity (1.4–1.6 cm) against all tested silver nanoparticle concentrations. None of the tested bacterial isolates except for P. mirabilis SCDR1 showed any resistance against silver-nanoparticles, even against the lowest concentration (50 ppm). Furthermore, Table 2 shows the resistance of P. mirabilis SCDR1 against colloidal Nanosilver assessed by a minimal inhibitory concentration method, compared with other tested Gram positive and negative bacterial species. Once more, P. mirabilis SCDR1 showed high resistance against the gradually increased concentrations of colloidal nanosilver. We observed P. mirabilis SCDR1 bacterial growth to colloidal Nanosilver concentration up to 500 ppm. On the other hand, K. pneumoniae showed the highest sensitivity against silver nanoparticles, with no observed growth at only 100 ppm colloidal nanosilver concentration. In addition, both E. coli and P. aeruginosa showed high sensitivity against silver nanoparticles, with no observed growth at 150 ppm colloidal Nanosilver concentration. Conversely, S. aureus tolerated only 200 ppm colloidal Nanosilver concentration. Similarly, Table 3 shows the resistance of P. mirabilis SCDR1 against silver and Nanosilver composite assessed by disk diffusion method. Nanosilver chitosan composites, with a concentration ranging from between 0.1% and 0.01 M to 3.2% and 0.16 M from chitosan and Silver nitrate respectively, had a comparable killing effect on both Gram positive and negative bacterial, namely S. aureus and P. aeruginosa. Meanwhile, none of the tested Nanosilver chitosan composites had any killing effect on P. mirabilis SCDR1. Similarly, all the tested commercially available silver and Nanosilver containing wound dressing bandages showed the enhanced killing effect on both S. aureus and P. aeruginosa. However, all these wound dressing bandages failed to inhibit P. mirabilis SCDR1 growth. P. mirabilis SCDR1 was able to produce strong biofilm with OD of 0.296.
Table 1
Resistance of P. mirabilis SCDR1 against colloidal Nano-Silver assessed by desk diffusion method
S. No.
Sample ID
Zone Of Inhibition (cm) S. aureus
Zone Of Inhibition (cm) E. cloacae
Zone Of Inhibition (cm) P. aeruginosa
Zone Of Inhibition (cm) E. coli
Zone Of Inhibition (cm) K. pneumoniae
Zone Of Inhibition (cm) P. mirabilis SCDR1
1
200 ppm
1.6 cm
1.5 cm
1.4 cm
1.1 cm
1.9 cm
0.0 cm
2
150 ppm
1.5 cm
1.2 cm
1.3 cm
1.0 cm
1.7 cm
0.0 cm
3
100 ppm
1.5 cm
1.2 cm
1.3 cm
1.0 cm
1.6 cm
0.0 cm
4
50 ppm
1.4 cm
1.1 cm
1.1 cm
0.9 cm
1.5 cm
0.0 cm
Table 2
Resistance of P. mirabilis SCDR1 against colloidal Nanosilver assessed by minimal inhibitory concentration method
AgNPs (concentration in ppm)
 
Bacterial species/strain
S. aureus ATCC 29213
P. aeruginosa ATCC 27853
E. cloacae ATCC 29212
E. coli ATCC 25922
K. pneumoniae ATCC 700603
P. mirabilis SCDR1
P. mirabilis ATCC 29906
50
Growth
Growth
Growth
Growth
Growth
Growth
Growth
100
Growth
Growth
Growth
Growth
No Growth
Growth
Growth
150
Growth
No Growth
Growth
No Growth
No Growth
Growth
Growth
200
Growth
No Growth
Growth
No Growth
No Growth
Growth
Growth
250
No Growth
No Growth
No Growth
No Growth
No Growth
Growth
Growth
300
No Growth
No Growth
No Growth
No Growth
No Growth
Growth
Growth
350
No Growth
No Growth
No Growth
No Growth
No Growth
Growth
Growth
400
No Growth
No Growth
No Growth
No Growth
No Growth
Growth
Growth
450
No Growth
No Growth
No Growth
No Growth
No Growth
Growth
Growth
500
No Growth
No Growth
No Growth
No Growth
No Growth
Growth
No Growth
550
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
600
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
650
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
700
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
S. aureus: 250 ppm/7.5
P. aeruginosa: 150 ppm/7.5
E. cloacae: 250 ppm/7.5
P. mirabilis SCDR1: 550 ppm/7.5
P. mirabilis ATCC: 500 ppm/7.5
Table 3
Resistance of P. mirabilis SCDR1 against silver and Nanosilver composite assessed by desk diffusion method
Sample ID
Zone Of Inhibition (cm)
Zone Of Inhibition (cm)
Zone Of Inhibition (cm)
S. aureus
P. aeruginosa
P. mirabilis SCDR1
A
0.9 cm
0.8 cm
No. Inhibition
B
0.9 cm
0.9 cm
No. Inhibition
C
0.8 cm
0.9 cm
No. Inhibition
D
0.8 cm
0.9 cm
No. Inhibition
E
0.9 cm
0.9 cm
No. Inhibition
F
0.8 cm
0.8 cm
No. Inhibition
G
0.7 cm
0.7 cm
No. Inhibition
H
0.9 cm
0.9 cm
No. Inhibition
I
0.9 cm
1.0 cm
No. Inhibition
J
0.9 cm
1.0 cm
No. Inhibition
K
0.8 cm
0.6 cm
No. Inhibition
L
0.8 cm
0.8 cm
No. Inhibition
M
0.9 cm
0.8 cm
No. Inhibition
N
0.9 cm
0.9 cm
No. Inhibition
O
1.0 cm
0.9 cm
No. Inhibition
P
0.8 cm
0.8 cm
No. Inhibition
Q
0.9 cm
0.7 cm
No. Inhibition
R
0.9 cm
0.8 cm
No. Inhibition
S
0.8 cm
0.9 cm
No. Inhibition
T
1.0 cm
0.9 cm
No. Inhibition
U
0.8 cm
0.8 cm
No. Inhibition
V
0.9 cm
0.8 cm
No. Inhibition
W
0.9 cm
0.8 cm
No. Inhibition
X
1.0 cm
0.8 cm
No. Inhibition
Y
0.8 cm
0.8 cm
No. Inhibition
Z
0.7 cm
0.7 cm
No. Inhibition
A1
0.8 cm
0.7 cm
No. Inhibition
B2
0.9 cm
0.7 cm
No. Inhibition
C3
0.9 cm
0.8 cm
No. Inhibition
D4
0.6 cm
NA
No. Inhibition
Silvercel
1.3 cm
1.4 cm
No. Inhibition
Sorbsan silver
1.9 cm
2.0 cm
No. Inhibition
Colactive® Plus Ag
1.5 cm
2.0 cm
No. Inhibition
Exsalt™ SD7
1.5 cm
1.5 cm
No. Inhibition
Puracol ® Plus Ag
1.4 cm
2.0 cm
No. Inhibition
Actisorb® Silver 220
0.9 cm
1.2 cm
No. Inhibition

General genome features

Data from our draft genome of P. mirabilis SCDR1 was deposited in the NCBI-GenBank and was assigned accession number LUFT00000000. The bacterial bioinformatics database and analysis resource (PATRIC) gene annotation analysis showed the presence 308 unique genes of the biosynthesis of secondary metabolites such as tetracycline, Streptomycin, Novobiocin, and Betalain. It is also noteworthy that Xenobiotics Biodegradation and Metabolism pathways also maintained a high number of dedicated unique gene (245) (Additional files 1 and 2: Tables S1 and S2).

Pathogen identification and phylogenetic analysis

As previously stated, biochemical identification of the isolate confirmed the identity of our isolate as belonging to the Proteus mirabilis species. Moreover, Primary analysis of Metaphlan showed that Proteus mirabilis is the most dominant species in the sample (Fig. 1). The appearance of other bacterial species in the Metaphlan diagram is explained by the genomic homology similarity of other bacteria to Proteus mirabilis. P. mirabilis SCDR1 genome showed high similarly, 92.07%, to the genome of P. mirabilis strain BB2000 followed by P. mirabilis strain C05028 (90.99%) and P. mirabilis strain PR03 (89.73%) (Table 4). A similar scenario was observed when constructing the phylogenetic relationship between our isolate and other Proteus mirabilis available in the NCBI- GenBank. 16Sr DNA-based maximum likelihood phylogenetic tree (Fig. 2) showed that our isolate is located within a large clade that contains the majority of Proteus mirabilis strains and isolates. In addition, P. mirabilis SCDR1 was shown to be closely related to the reference strain P. mirabilis HI4320 compared with P. mirabilis BB2000, which is located in another clade of four Proteus mirabilis taxa. On the contrary, the whole genome Neighbor-joining phylogenetic tree of Proteus mirabilis spices including P. mirabilis SCDR1 isolate (Fig. 3), showed that our isolate was more closely related to P. mirabilis BB2000 compared with the reference strain/genome P. mirabilis HI4320. However, Fig. 4 showed that P. mirabilis SCDR1 exhibited obvious genetic divergence from other Proteus mirabilis species. Similar results were observed when performing pairwise pair-wise whole genome alignment of P. mirabilis strain SCDR1 against reference genomes (Fig. 4). This was also confirmed with the clear divergence among P. mirabilis SCDR1 Proteus mirabilis species at the proteomic level (Fig. 5).
Table 4
Comparison of Proteus mirabilis SCDR1 to complete and draft reference genomes of Proteus mirabilis
NCBI ID
Reference
Ref Size
Gaps sum length
Gaps > = 100 bp
Bases sum length
Bases >500 bp
% Reference
Completed Genomes
 NC_010554.1
Proteus mirabilis HI4320
4,063,606
555,251
549,285
3,508,355
3,472,919
86.33
 NC_010555.1
Proteus mirabilis plasmid pHI4320
36,289
36,289
36,289
0
0
0
 NC_022000.1
Proteus mirabilis BB2000
3,846,754
304,708
298,947
3,542,046
3,510,682
92.07
Draft Genomes
 NZ_ACLE00000000
Proteus mirabilis ATCC_29,906
4,027,100
565,180
560,679
3,461,920
3,432,786
85.96
 NZ_ANBT00000000
Proteus mirabilis C05028
3,817,619
343,688
338,218
3,473,931
3,445,432
90.99
 NZ_AORN00000000
Proteus mirabilis PR03
3,847,612
394,926
390,203
3,452,686
3,430,536
89.73
 NZ_AMGU00000000
Proteus mirabilis WGLW4
3,960,485
474,704
469,864
3,485,781
3,458,264
88.01
 NZ_AMGT00000000
Proteus mirabilis WGLW6
4,101,891
606,773
601,555
3,495,118
3,461,467
85.20

Bacterial pathogenic and virulence factors

Pathogenomics analysis using PathogenFinder 1.1 showed that our input organism was predicted as a human pathogen, and the probability of being a human pathogen was 0.857. P. mirabilis SCDR1 comparative proteome analysis showed 35 matched hits from pathogenic families and only one hit from non-pathogenic families (Additional file 3: Table S3). In addition, genome analysis showed that P. mirabilis SCDR1 isolate contains numerous virulence factor genes and/or operons that marks it out to be a virulent pathogenic bacterium. These virulence factors include swarming behavior, mobility (flagellae), adherence, toxin and hemolysin production, Urease, Quorum sensing, iron acquisition systems, proteins that function in immune evasion, cell invasion and biofilm formation, stress tolerance factors, and chemotaxis related factors (Additional file 4: Table S4).

Proteus Mirabilis SCDR1 Resistome

Antibiotic resistance

Antibiotic resistance identification Perfect and Strict analysis using Resistance Gene Identifier (RGI) showed that P. mirabilis SCDR1 isolate contains 34 antibiotic resistance genes that serve in 21 antibiotic resistance functional categories (Additional file 5: Table S5 and Fig. 6). Meanwhile, using the less strict (Loose) antibiotic resistance identification criteria identified 3750 hits in P. mirabilis SCDR1 genome that represent potential AROs (Antibiotic Resistance Ontology) that fall into 59 antibiotic resistance functional categories (Fig. 7) of which 38 are considered to lose antibiotic resistance functional categories. Modified loose antibiotic resistance identification criteria, by removing all hits with objectionable e-values, lead to a number of 366 antibiotic resistance related hits (Additional file 6: Table S6 and Fig. 7). Manual genome annotation based mining resulted in the identification of 64 drug resistance related proteins in P. mirabilis SCDR1 genome (Additional file 7: Table S7).

Proteus Mirabilis comparative genomics based resistome analysis

We performed a species-wide antibiotic resistome constituent analysis of P. mirabilis. All available P. mirabilis genomes, including the P. mirabilis SCDR1 genome, were included in this analysis (Table 5). Results of our analysis (Table 6 and Fig. 8) showed that the number of the observed antimicrobial resistance based ontologies (AMRO) in P. mirabilis genomes is 61. Only 16 AMROs were observed amongst all the studied 56 P. mirabilis genomes. Meanwhile, 13 AMROs were observed amongst 55 P. mirabilis genomes. In addition, only four AMROs were observed amongst 54 P. mirabilis genomes and two AMROs were observed amongst 48 P. mirabilis genomes. This suggests that the core constituent of antibiotic resistome of P. mirabilis species is made up of 35 AMROs (Table 6). On the other hand, eight AMROs were detected only in one P. mirabilis genome. For example, the membrane fusion component of tripartite multidrug resistance system was only observed in our P. mirabilis SCDR1 genome.
Table 5
Proteus mirabilis genomes represented in the species wide comparative genomics antibiotic resistance analysis
Genome/Strain Name
Genome Status
GenBank Accessions
P. mirabilis ATCC 29906
WGS
ACLE00000000
P. mirabilis BB2000
Complete
CP004022.1
P. mirabilis C05028
WGS
ANBT00000000
P. mirabilis HI4320
Complete
AM942759,AM942760
P. mirabilis PR03
WGS
AORN00000000
P. mirabilis SCDR1
WGS
LUFT00000000
P. mirabilis WGLW4
WGS
AMGU00000000
P. mirabilis WGLW6
WGS
AMGT00000000
P. mirabilis strain 1114_PMIR
WGS
JWCS01000000
P. mirabilis strain 1134_PMIR
WGS
JWBY01000000
P. mirabilis strain 1150_PMIR
WGS
JWBG01000000
P. mirabilis strain 1166_PMIR
WGS
JWAP01000000
P. mirabilis strain 127_PMIR
WGS
JVWE01000000
P. mirabilis strain 1293_PMIR
WGS
JVVD01000000
P. mirabilis strain 1310_PMIR
WGS
JVUH01000000
P. mirabilis strain 1313_PMIR
WGS
JVUE01000000
P. mirabilis strain1326_PMIR
WGS
JVTO01000000
P. mirabilis strain1330_PMIR
WGS
JVTJ01000000
P. mirabilis strain 232_PMIR
WGS
JVPB01000000
P. mirabilis strain 25,933 GTA
WGS
LANL01000000
P. mirabilis strain 25_PMIR
WGS
JVOK01000000
P. mirabilis strain 292_PMIR
WGS
JVMQ01000000
P. mirabilis strain 360_PMIR
WGS
JVKD01000000
P. mirabilis strain 373_PMIR
WGS
JVJQ01000000
P. mirabilis strain 418_PMIR
WGS
JVHX01000000
P. mirabilis strain 429_PMIR
WGS
JVHK01000000
P. mirabilis strain 430_PMIR
WGS
JVHI01000000
P. mirabilis strain 47_PMIR
WGS
JVFU01000000
P. mirabilis strain 50,664,164
WGS
LNHT01000000
P. mirabilis strain 51_PMIR
WGS
JVEH01000000
P. mirabilis strain 646_PMIR
WGS
JUYT01000000
P. mirabilis strain 672_PMIR
WGS
JUXR01000000
P. mirabilis strain 68_PMIR
WGS
JUXK01000000
P. mirabilis strain AOUC-001
Complete
CP015347
P. mirabilis strain ATCC 7002
WGS
JOVJ00000000
P. mirabilis strain C02011
WGS
KV388086,KV388087,KV388088, KV388089,KV388090,KV388091,
KV388092,LAGU00000000
P. mirabilis strain CYPM1
Complete
CP012674
P. mirabilis strain FDAARGOS 60
Complete
JTBW01000000
P. mirabilis strain FDAARGOS 67
Complete
JTBP01000000
P. mirabilis strain FDAARGOS 80
WGS
JTBB01000000
P. mirabilis strain FDAARGOS 81
Complete
JTBA01000000
P. mirabilis strain FDAARGOS 85
WGS
JTAW01000000
P. mirabilis strain GB08
WGS
LQNN00000000
P. mirabilis strain GB11
WGS
LQNO00000000
P. mirabilis strain GED7834
WGS
KQ960957,KQ960958,KQ960959,KQ960960,
KQ960961,KQ960962,KQ960963,KQ960964,
KQ960965,KQ960966,KQ960967,KQ960968,
KQ960969,KQ960970,KQ960971,KQ960972,
KQ960973,KQ960974,KQ960975,KQ960976,
KQ960977,KQ960978,KQ960979,KQ960980,
KQ960981,KQ960982,KQ960983,KQ960984,
KQ960985,KQ960986,KQ960987,KQ960988,
KQ960989,KQ960990,KQ960991,KQ960992,
KQ960993,KQ960994,KQ960995,KQ960996,
KQ960997,KQ960998,KQ960999,KQ961000,
KQ961001,KQ961002,KQ961003,KQ961004
,KQ961005,KQ961006,KQ961007,KQ961008,
KQ961009,KQ961010,KQ961011,KQ961012,
KQ961013,KQ961014,KQ961015,KQ961016,
KQ961017,KQ961018
P. mirabilis strain M16
WGS
LQQZ00000000
P. mirabilis strain NIVEDI3-PG74
WGS
LWDB00000000
P. mirabilis strain NO-051/03
WGS
LGAY01000000
P. mirabilis strain PM593
WGS
JSUP01000000
P. mirabilis strain PM655
WGS
JSUO01000000
P. mirabilis strain PM_125
WGS
LWUL00000000
P. mirabilis strain PM_178
WGS
LWUM00000000
P. mirabilis strain Pm-Oxa48
WGS
JSCB01000000
P. mirabilis strain Pr2921
WGS
LGTA00000000
P. mirabilis strain SAS71
WGS
LDIU01000000
P. mirabilis strain Wood
WGS
LTBK00000000
Table 6
Species wide Proteus mirabilis antibiotic resistome constituents
Antimicrobial Resistance based ontology (AMRO)
Number of Genomes shared AMRO
6′-N-acetyltransferase
4
Aminoglycoside 3′-phosphotransferase @ Streptomycin 3′-kinase StrA
13
Aminoglycoside 3′-phosphotransferase
16
Putative transport protein ARO:3,001,215, ARO:1,000,001
48
Beta-lactamase
14
Bicyclomycin resistance protein
3
Chloramphenicol acetyltransferase
54
COG0488: ATPase components of ABC transporters with duplicated ATPase domains
1
Copper sensory histidine kinase CpxA
56
Copper-sensing two-component system response regulator CpxR
56
Cyclic AMP receptor protein
56
Dihydropteroate synthase
56
Dihydropteroate synthase type-2 @ Sulfonamide resistance protein
16
DNA gyrase subunit A
56
DNA-binding protein H-NS
55
DNA-directed RNA polymerase beta subunit
56
Ethidium bromide-methyl viologen resistance protein EmrE
55
Gentamicin 3′-N-acetyltransferase
2
Hypothetical protein ARO: 3,000,230, ARO: 1,000,001
2
Streptomycin 3″-O-adenylyltransferase @ Spectinomycin 9-O-adenylyltransferase
5
Macrolide export ATP-binding/permease protein MacB
56
Macrolide-specific efflux protein MacA
55
Membrane fusion component of tripartite multidrug resistance system
1
MFS superfamily export protein YceL
55
Mobile element protein ARO: 3,000,903, ARO: 1,000,001
9
Multi antimicrobial extrusion protein (Na (+)/drug antiporter), MATE family of MDR efflux pumps
56
Multidrug resistance protein D. ARO: 3,000,309, ARO: 1,000,001
56
Multidrug resistance protein ErmA
55
Multidrug resistance protein ErmB
56
Multidrug transporter MdtB
56
Multidrug transporter MdtC
56
Multidrug-efflux transporter, major facilitator superfamily (MFS)
54
N-3-oxohexanoyl-L-homoserine lactone quorum-sensing transcriptional activator
1
Outer membrane porin OmpF
54
Outer membrane protein F precursor
1
Probable RND efflux membrane fusion protein
1
Putative transport protein ARO: 3,001,215, ARO: 1,000,001
48
Redox-sensitive transcriptional activator SoxR
55
Response regulator BaeR
56
Ribosomal RNA methyltransferase
1
Rifampin ADP-ribosyl transferase
3
RND efflux system, inner membrane transporter ARO: 3,000,216, ARO: 1,000,001
2
RND efflux system, inner membrane transporter: Aminoglycoside, Glycylcycline, Beta_lactam, Macrolide, Acriflavin
3
RND efflux system, inner membrane transporter Aminoglycoside, Glycylcycline, Beta_lactam, Macrolide, Acriflavin ARO: 3,000,216, ARO: 1,000,001
3
RND efflux system, membrane fusion protein (acrA, ARO: 1,000,001, ARO: 3,000,207) OR (mdtA, ARO: 1,000,001, ARO: 3,000,792)
56
RND multidrug efflux transporter; Acriflavin resistance protein
2
Sensor histidine kinase PhoQ
55
Sensory histidine kinase BaeS
56
SSU rRNA (adenine (1518)-N (6)/adenine (1519)-N (6))-dimethyltransferase
1
Streptomycin 3″-O-adenylyltransferase @ Spectinomycin 9-O-adenylyltransferase (spectinomycin, streptomycin) (ARO: 1,000,001, ARO: 3,000,232) (tobramycin,gentamicin, dibekacin, sisomicin, kanamycin)
9
Tetracycline efflux protein TetA
55
Topoisomerase IV subunit A
54
Transcription repressor of multidrug efflux pump acrAB operon, TetR (AcrR) family
3
Transcriptional regulator of acrAB operon, AcrR
56
Transcriptional regulatory protein PhoP
55
Transcriptional repressor MprA
55
Translation elongation factor Tu
55
TrkA-N: Sodium/hydrogen exchanger
3
Two-component system response regulator OmpR
55
Type I secretion outer membrane protein, TolC precursor
55
UDP-4-amino-4-deoxy-L-arabinose formyltransferase/ UDP-glucuronic acid oxidase (UDP-4-keto-hexauronic acid decarboxylating)
1

Consensus P. mirabilis-SCDR1 antibiotic Resistome

Table 7 displays the consensus P. mirabilis-SCDR1 antibiotic resistome. Genomics analysis of P. mirabilis-SCDR1 63 contigs showed that our isolates contained genetic determinants for tetracycline resistance (tetAJ), fluoroquinolones resistance (gyrA, parC and parE), sulfonamide resistance (folP), daptomycin and rifamycin resistance (rpoB), elfamycin antibiotics resistance (tufB), Chloramphenicol (cpxR, cpxA and cat), ethidium bromide-methyl viologen resistance protein (emrE) and polymyxin resistance (phoP). In addition, several multidrug resistance efflux systems and complexes such as MdtABC-TolC, MacAB-TolC, AcrAB-TolC, EmrAB-TolC, AcrEF-TolC and MATE.
Table 7
Consensus P. mirabilis-SCDR1 antibiotic Resistome
Source
Source Organism
Gene
Product
Function
Query Coverage
Identity
E-value
ARDB
P. mirabilis ATCC 29906
tetAJ
Tetracycline efflux protein TetA
Major facilitator superfamily transporter, tetracycline efflux pump.
97
95
0
CARD
P. mirabilis BB2000
tetAJ
Tetracycline efflux protein TetA
Major facilitator superfamily transporter, tetracycline efflux pump.
97
94
0
ARDB
P. mirabilis HI4320
tetAJ
Tetracycline efflux protein TetA
Major facilitator superfamily transporter, tetracycline efflux pump.
80
99
2e-74
CARD
P. mirabilis BB2000
gyrA
DNA gyrase subunit A (EC 5.99.1.3)
Point mutation of Escherichia coli gyrA resulted in the lowered affinity between fluoroquinolones and gyrA. Thus, conferring resistance
98
99
0
CARD
P. mirabilis BB2000
baeR
Response regulator BaeR
BaeR is a response regulator that promotes the expression of MdtABC and AcrD efflux complexes.
100
99
2e-171
CARD
P. mirabilis BB2000
baeS
Sensory histidine kinase BaeS
BaeS is a sensor kinase in the BaeSR regulatory system. While it phosphorylates BaeR to increase its activity.
100
99
0
CARD
P. mirabilis BB2000
mdtC
Multidrug transporter MdtC
MdtC is a transporter that forms a hetero-multimer complex with MdtB to form a multidrug transporter. MdtBC is part of the MdtABC-TolC efflux complex.
100
99
0
CARD
P. mirabilis BB2000
mdtB
Multidrug transporter MdtB
MdtB is a transporter that forms a heteromultimer complex with MdtC to form a multidrug transporter. MdtBC is part of the MdtABC-TolC efflux complex.
100
99
0
CARD
P. mirabilis BB2000
mdtA
RND efflux system, membrane fusion protein
MdtA is the membrane fusion protein of the multidrug efflux complex mdtABC.
100
98
0
CARD
P. mirabilis BB2000
folP
Dihydropteroate synthase (EC 2.5.1.15)
Point mutations in dihydropteroate synthase folP prevent sulfonamide antibiotics from inhibiting its role in folate synthesis, thus conferring sulfonamide resistance.
100
100
0
CARD
P. mirabilis BB2000
soxR
Redox-sensitive transcriptional activator SoxR
SoxR is a sensory protein that upregulates soxS expression in the presence of redox-cycling drugs. This stress response leads to the expression many multidrug efflux pumps.
100
100
0
CARD
Shigella dysenteriae Sd197
ompR
Two-component system response regulator OmpR
Transcriptional regulatory protein
99
87
0
CARD
P. mirabilis BB2000
emrR
Transcriptional repressor MprA
EmrR is a negative regulator for the EmrAB-TolC multidrug efflux pump in E. coli. Mutations lead to EmrAB-TolC overexpression.
100
100
0
CARD
P. mirabilis BB2000
emrA
Multidrug resistance protein ErmA
EmrA is a membrane fusion protein, providing an efflux pathway with EmrB and TolC between the inner and outer membranes of E. coli, a Gram-negative bacterium.
95
96
0
CARD
P. mirabilis BB2000
acrE
Membrane fusion component of tripartite multidrug resistance system
AcrEF-TolC is a tripartite multidrug efflux system similar to AcrAB-TolC and found in Gram-negative bacteria. AcrE is the membrane fusion protein, AcrF is the inner membrane transporter, and TolC is the outer membrane channel protein.
100
98
3e-44
CARD
P. mirabilis BB2000
emrB
Multidrug resistance protein ErmB
emrB is a translocase in the emrB -TolC efflux protein in E. coli. It recognizes substrates including carbonyl cyanide m-chlorophenylhydrazone (CCCP), nalidixic acid, and thioloactomycin.
100
99
0
CARD
P. mirabilis BB2000
rpoB
DNA-directed RNA polymerase beta subunit (EC 2.7.7.6)
Mutations in rpoB gene confers antibiotic resistance (Daptomycin and Rifamycin)
100
99
0
CARD
P. mirabilis BB2000
tufB
Translation elongation factor Tu
Sequence variants of elongation factor Tu confer resistance to elfamycin antibiotics.
100
100
1e-43
CARD
P. mirabilis BB2000
cpxA
Copper sensory histidine kinase CpxA
cpxA mutant confer resistant to amikacin
94
99
0
CARD
P. mirabilis BB2000
cpxR
Copper-sensing two-component system response regulator CpxR
CpxR is a regulator that promotes acrD expression when phosphorylated by a cascade involving CpxA, a sensor kinase. Cefepime and chloramphenicol
100
100
0
CARD
P. mirabilis BB2000
emrD
Multidrug resistance protein D
EmrD is a multidrug transporter from the Major Facilitator Superfamily (MFS) primarily found in Escherichia coli. EmrD couples efflux of amphipathic compounds with proton import across the plasma membrane.
100
99
0
CARD
P. mirabilis BB2000
macA
Macrolide-specific efflux protein MacA
MacA is a membrane fusion protein that forms an antibiotic efflux complex with MacB and TolC.
100
99
3e-177
CARD
P. mirabilis BB2000
macB
Macrolide export ATP-binding/permease protein MacB (EC 3.6.3.-)
MacB is an ATP-binding cassette (ABC) transporter that exports macrolides with 14- or 15- membered lactones. It forms an antibiotic efflux complex with MacA and TolC.
100
98
0
ARDB
P. mirabilis ATCC 29906
cat
Chloramphenicol acetyltransferase (EC 2.3.1.28)
Group A chloramphenicol acetyltransferase, which can inactivate chloramphenicol.
99
93
6e-150
CARD
P. mirabilis BB2000
cat
Chloramphenicol acetyltransferase (EC 2.3.1.28)
Group A chloramphenicol acetyltransferase, which can inactivate chloramphenicol.
99
93
4e-151
CARD
P. mirabilis BB2000
acrR
Transcription repressor of multidrug efflux pump acrAB operon, TetR (AcrR) family
AcrR is a repressor of the AcrAB-TolC multidrug efflux complex. AcrR mutations result in high level antibiotic resistance.
100
95
9e-25
CARD
P. mirabilis BB2000
acrR
Transcriptional regulator of acrAB operon, AcrR
AcrR is a repressor of the AcrAB-TolC multidrug efflux complex. AcrR mutations result in high level antibiotic resistance.
93
95
2e-114
CARD
P. mirabilis BB2000
acrA
RND efflux system, membrane fusion protein
Protein subunit of AcrA-AcrB-TolC multidrug efflux complex. AcrA represents the periplasmic portion of the transport protein.
100
99
0
CARD
P. mirabilis BB2000
mdtK
Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
A multidrug and toxic compound extrusions (MATE) transporter conferring resistance to norfloxacin, doxorubicin and acriflavine.
98
99
3e-164
CARD
Salmonella enterica subsp. enterica serovar Agona str. SL483
hns
DNA-binding protein H-NS
H-NS is a histone-like protein involved in global gene regulation in Gram-negative bacteria. It is a repressor of the membrane fusion protein genes acrE, mdtE, and emrK as well as nearby genes of many RND-type multidrug exporters.
100
80
0
CARD
P. mirabilis BB2000
tufB
Translation elongation factor Tu
Sequence variants of elongation factor Tu confer resistance to elfamycin antibiotics.
100
99
0
CARD
Shigella dysenteriae Sd197
crp
Cyclic AMP receptor protein
CRP is a global regulator that represses MdtEF multidrug efflux pump expression.
100
98
0
CARD
P. mirabilis BB2000
emrE
Ethidium bromide-methyl viologen resistance protein EmrE
EmrE is a small multidrug transporter that functions as a homodimer and that couples the efflux of small polyaromatic cations from the cell with the import of protons down an electrochemical gradient. EmrE is found in E. coli and P. aeruginosa.
100
99
6e-73
CARD
P. mirabilis BB2000
mdtK
Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
A multidrug and toxic compound extrusions (MATE) transporter conferring resistance to norfloxacin, doxorubicin and acriflavine.
100
100
2e-113
CARD
P. mirabilis BB2000
NIA
Putative transport protein
NIA
100
94
7e-59
CARD
P. mirabilis BB2000
NIA
Multidrug resistance protein
NIA
99
96
2e-112
CARD
P. mirabilis BB2000
parC
Topoisomerase I subunit A (EC 5.99.1.-)
ParC is a subunit of topoisomerase IV, which decatenates and relaxes DNA to allow access to genes for transcription or translation. Point mutations in ParC prevent fluoroquinolone antibiotics from inhibiting DNA synthesis, and confer low-level resistance. Higher-level resistance results from both gyrA and parC mutations.
99
99
0
CARD
P. mirabilis BB2000
parE
Topoisomerase IV subunit B (EC 5.99.1.-)
ParE is a subunit of topoisomerase IV, necessary for cell survival. Point mutations in ParE prevent fluoroquinolones from inhibiting DNA synthesis, thus conferring resistance.
100
99
0
CARD
P. mirabilis BB2000
tolC
Type I secretion outer membrane protein, TolC precursor
TolC is a protein subunit of many multidrug efflux complexes in Gram negative bacteria. It is an outer membrane efflux protein and is constitutively open. Regulation of efflux activity is often at its periplasmic entrance by other components of the efflux complex.
100
99
0
CARD
P. mirabilis BB2000
mdtH
MFS superfamily export protein YceL
Multidrug resistance protein MdtH
100
99
0
CARD
P. mirabilis BB2000
phoP
Transcriptional regulatory protein PhoP
A mutant phoP activates pmrHFIJKLM expression responsible for L-aminoarabinose synthesis and polymyxin resistance, by way of alteration of negative charge
100
99
5e-165
CARD
P. mirabilis BB2000
phoQ
Sensor histidine kinase PhoQ (EC 2.7.13.3)
Mutations in Pseudomonas aeruginosa PhoQ of the two-component PhoPQ regulatory system. Presence of mutation confers resistance to colistin
90
99
0
CARD
P. mirabilis BB2000
phoQ
Sensor histidine kinase PhoQ (EC 2.7.13.3)
Mutations in Pseudomonas aeruginosa PhoQ of the two-component PhoPQ regulatory system. Presence of mutation confers resistance to colistin
98
98
1e-45
Evidence: BLASTP, NIA: No information available, ARDB: Antibiotic Resistance Genes Database, CARD: Comprehensive Antibiotic Resistance Database
• MdtC: In the absence of MdtB, MdtC can form a homomultimer complex that results in a functioning efflux complex with a narrower drug specificity
• Elongation factor Tu is required for peptide elongation in bacterial protein synthesis
• cpxR Srinivasan VB, et al. 2012. PLoS One 7(4): E33777. Role of the two component signal transduction system CpxAR in conferring cefepime and chloramphenicol resistance in Klebsiella pneumoniae NTUH-K2044. (PMID 22496764)
• MacAB-TolC: MacAB-TolC is an ABC efflux pump complex expressed in E. coli and Salmonella enterica. It confers resistance to macrolides, including erythromycin

Heavy metal resistance

Table 8 presents P. mirabilis SCDR1 heavy metal resistance/binding factors. Numerous genetic determinants for metal resistance were observed in the P. mirabilis SCDR1 genome. Several Copper resistance genes/proteins were detected, namely, copA, copB, copC, copD, cueO, cueR, cutC, cutF and CuRO_2_CopA_like1. In addition, gene determinants of Copper/silver efflux system were observed, namely, oprB, oprM and cusC_1. Moreover, several heavy metal resistance proteins and efflux systems were observed, such as magnesium/cobalt efflux protein CorC, metal resistance proteins (AGS59089.1, AGS59090.1 and AGS59091.1), nickel-cobalt-cadmium resistance protein NccB, arsenical pump membrane protein (ArsB permease), Lead, cadmium, zinc and mercury transporting ATPase, outer membrane component of tripartite multidrug resistance system (CusC) and complete P. mirabilis tellurite resistance loci (terB, terA, terC, terD, terE, terZ). Furthermore, enzymes involved in heavy metal resistance were also observed such as glutathione S-transferase (gst1, gst, Delta and Uncharacterized), arsenite S-adenosylmethyltransferase (Methyltransferase type 11) and alkylmercury lyase (MerB).
Table 8
P. mirabilis SCDR1 Heavy Metal Resistance/Binding factors
Annotation
Reference Genome
Accession Number
Gene
Protein ID
AA Length
Corresponding Protein
PATRIC
P. mirabilis ATCC 29906
NZ_GG668580
corC
ZP_03842837.1
293
Magnesium/cobalt efflux protein CorC.
RefSeq
P. mirabilis BB2000
CP004022
NA
AGS60530.1
305
cation efflux protein (Divalent metal cation (Fe/Co/Zn/Cd) transporter).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668576
cueR
ZP_03840921.1
133
MerR-family transcriptional regulator (copper efflux regulator).
RefSeq
P. mirabilis BB2000
CP004022
arsB
AGS60689.1
429
Arsenical pump membrane protein (ArsB_permease).
RefSeq
P. mirabilis BB2000
CP004022
NA
AGS59089.1
AGS59090.1
AGS59091.1
129
678
243
Metal resistance protein.
PATRIC
P. mirabilis ATCC 29906
P. mirabilis strain 25,933 GTA
NZ_GG668576
LANL01000027
ahpF
NA
ZP_03839875.1
KKC60389.1
521
678
Protein-disulfide reductase.
PATRIC
P. mirabilis ATCC 29906
NZ_GG668576
NZ_GG668583
dsbB
dsbA
ZP_03840198.1
ZP_03839563.1
174
207
Protein disulfide oxidoreductase.
PATRIC
P. mirabilis ATCC 29906
P. mirabilis BB2000
NZ_GG668576
NZ_GG668576
NZ_GG668578
CP004022
actP1
copA
ppaA
zntA
ZP_03840801.1
ZP_03840922.1
ZP_03842696.1
AGS58561.1
829
984
803
796
(zinc/cadmium/mercury/lead-transporting ATPase) (HMA).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668578
gloB
ZP_03842342.1
251
hydroxyacylglutathione hydrolase.
RefSeq
P. mirabilis strain ATCC 7002
JOVJ01000008
grxA
KGA90223.1
87
Glutaredoxin, GrxA family.
PATRIC
P. mirabilis ATCC 29906
P. mirabilis strain 1134_PMIR
NZ_GG668576
NZ_GG668576
gst1
gst
Delta
Uncharacterized
ZP_03840532.1
ZP_03840063.1
PGF_02913068a
PGF_00008413a
204
203
195
110
Glutathione S-transferase (EC 2.5.1.18).
RefSeq
P. mirabilis BB2000
CP004022
cueO
AGS58840.1
526
Multicopper oxidase.
PATRIC
P. mirabilis ATCC 29906
NZ_GG668578
NA
ZP_03842149.1
243
FIG00003370: Multicopper polyphenol oxidase.
PATRIC
P. mirabilis strain ATCC 7002
JOVJ01000009
yobA
ZP_03839688.1
130
Copper resistance protein (Copper-binding protein CopC (methionine-rich)) [Inorganic ion transport and metabolism].
PATRIC
P. mirabilis ATCC 29906
NZ_GG668576
copD
ZP_03839689.1
279
Copper resistance protein.
PATRIC
P. mirabilis strain SAS71
LDIU01000481
NA
PGF_00419563
114
Copper resistance protein D.
BRC1
P. mirabilis HI4320
NC_010554
NA
NA
300
Putative copper resistance protein, secreted.
PATRIC
RefSeq
P. mirabilis ATCC 29906
NZ_GG668576
copC
ZP_03839688.1
130
Copper resistance protein CopC.
PATRIC
E. coli 7–233-03_S4_C2
JORW01000046
copB
KEN13242.1
296
Copper resistance protein B.
PATRIC
P. mirabilis ATCC 29906
NZ_GG668576
cutC
ZP_03839779.1
250
Copper homeostasis protein CutC (Cytoplasmic copper homeostasis protein CutC).
RefSeq
P. mirabilis BB2000
CP004022
cop A
AGS60771.1
904
Copper exporting ATPase.
PATRIC
P. mirabilis ATCC 29906
NZ_GG668576
cop A
ZP_03840922.1
949
Lead, cadmium, zinc and mercury transporting ATPase (EC 3.6.3.3) (EC 3.6.3.5); Copper-translocating P-type ATPase (EC 3.6.3.4).
RefSeq
P. mirabilis strain ATCC 7002
JOVJ01000009
kdpB
KGA89427.1
685
Copper exporting ATPase (potassium-transporting ATPase subunit B).
RefSeq
P. mirabilis
WP_012368272.1, WP_020946123.1
copA- CopZ- HMA
WP_012368272
WP_020946123
984
Copper exporting ATPase (Heavy-metal-associated domain (HMA)).
RefSeq
P. mirabilis strain ATCC 7002
JOVJ01000005
cueR
KGA91278.1
135
Copper -responsive transcriptional regulator (HTH_MerR-SF Superfamily).
PATRIC
P. mirabilis BB2000
P. mirabilis strain 1310_PMIR
CP004022
JVUH01000152
JVUH01001396
cutF
ZP_03841587.1
PGF_00241126a
PGF_00241126a
225
154
78
Copper homeostasis protein CutF precursor/Lipoprotein NlpE involeved in surface adhesion.
PATRIC
RefSeq
P. mirabilis BB2000
CP004022
terB
terA
terC
terD
terE
terZ
AGS60978.1
AGS60979.1
AGS60977.1
AGS60976.1
AGS60975.1
AGS60980.1
151
382
341
192
191
194
P. mirabilis tellurite resistance loci.
PATRIC
RefSeq
Mycobacterium sp.
YP_001705575.1
CP002992
ctpC
AEN01737.1
718
Probable cation-transporting ATPase G (ATPase-IB2_Cd).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668579
yntB
ZP_03841770.1
325
Nickel transport system permease protein nikB2 (TC 3.A.1.5.3).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668579
yntA
ZP_03841771.1
527
Nickel ABC transporter, periplasmic nickel-binding protein nikA2 (TC 3.A.1.5.3).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668583
NA
ZP_03839446.1
289
Nickel transport system permease protein NikC (TC 3.A.1.5.3).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668583
NA
ZP_03839447.1
269
Nickel transport ATP-binding protein NikD (TC 3.A.1.5.3).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668579
yntD
ZP_03841768.1
267
Nickel transport ATP-binding protein nikD2 (TC 3.A.1.5.3).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668579
yntE
ZP_03841767.1
203
Nickel transport ATP-binding protein nikE2 (TC 3.A.1.5.3).
PATRIC
P. mirabilis ATCC 29906
NZ_GG668579
yntC
ZP_03841769.1
270
Nickel transport system permease protein nikC2 (TC 3.A.1.5.3).
PATRIC
P. mirabilis BB2000
CP004022
hybF
AGS58541.1
113
[NiFe] hydrogenase nickel incorporation protein HypA.
PATRIC
P. mirabilis ATCC 29906
NZ_GG668578
hybB
ZP_03842517.1
282
[NiFe] hydrogenase nickel incorporation-associated protein HypB.
RefSeq
C. crescentus OR37
APMP01000019
NA
ENZ81282.1
723
Copper/silver/heavy metal-translocating P-type ATPase, Cd/Co/Hg/Pb/Zn-transporting.
RefSeq
Armatimonadetes bacterium OLB18
C. gilvus
JZQX01000123
WP_013884717.1
arsM
KXK16912.1
283
Arsenite S-adenosylmethyltransferase (Methyltransferase type 11).
RefSeq
R. palustris TIE-1
NC_011004
NA
YP_001990857.1
973
Heavy metal translocating P-type ATPase (ATPase-IB1_Cu).
RefSeq
M. ulcerans str. Harvey
EUA92940.1,
CuRO_2_CopA_like1
EUA92940.1
552
Multicopper oxidase family protein.
RefSeq
B. mallei NCTC 10229
NC_008835
oprB
YP_001024205.1
553
Copper/silver efflux system outer membrane protein CusC (outer membrane efflux protein OprB).
RefSeq
B. pseudomallei 576
NZ_ACCE01000001
oprM
ZP_03450560.1
558
Copper/silver efflux system outer membrane protein CusC (outer membrane efflux protein OprM).
PATRIC
RefSeq
Achromobacter sp. strain 2789STDY5608636
B. pseudomallei 1710b
CYTV01000008
ABA52627.1
cusC_1
ABA52627
515
Copper/silver efflux system outer membrane protein CusC (RND efflux system outer membrane lipoprotein).
RefSeq
Achromobacter sp. strain 2789STDY5608623
CYSZ01000001
NA
CUI29018.1
98
Outer membrane component of tripartite multidrug resistance system (CusC).
RefSeq
R. opacus
WP_012687282.1, BAH48260.1
merB
WP_012687282
334
Alkylmercury lyase (MerB).
PATRIC
RefSeq
B. ubonensis strain MSMB2185WGS
Q44585.1
LPIU01000068
NA
Q44585
PGF_01102114a
379
377
Nickel-cobalt-cadmium resistance protein NccB.
PATRIC
P. mirabilis BB2000
CP004022
zntA
AGS58561.1
798
Lead, cadmium, zinc and mercury transporting ATPase (EC 3.6.3.3) (EC 3.6.3.5); Copper-translocating P-type ATPase (EC 3.6.3.4)
PATRIC
P. mirabilis BB2000
CP004022
copA
AGS60771.1
949
Lead, cadmium, zinc and mercury transporting ATPase (EC 3.6.3.3) (EC 3.6.3.5); Copper-translocating P-type ATPase (EC 3.6.3.4).
PATRIC
P. mirabilis BB2000
CP004022
copA
AGS60770.1
54
Lead, cadmium, zinc and mercury transporting ATPase (EC 3.6.3.3) (EC 3.6.3.5); Copper-translocating P-type ATPase (EC 3.6.3.4).
NA Not availbe
aPATRIC cross-genus families (PGfams)

Discussion

Proteus mirabilis isolate was observed as mixed culture along with S. aureus isolate while testing our produced silver Nanoparticles against several pathogenic S. aureus isolates [9]. Whereas other tested Gram positive and negative bacteria showed great sensitivity against silver Nanoparticles, P. mirabilis, SCDR1 isolate exhibited extreme resistance. P. mirabilis SCDR1 isolate resistant against at least one antibiotic belonging to ansamycins, glycopeptides, fucidanes, cyclic peptides, nitroimidazoles, macrolides, lincosamides, folate pathway inhibitors and aminocoumarin antimicrobial categories. Moreover, our isolate exhibited intrinsic resistance against tetracyclines and polymyxins specific to P. mirabilis species [36, 52, 53]. However, fortunately, our isolate was sensitive to several operational antimicrobial categories such as penicillins with b-lactamase inhibitors, extended-spectrum cephalosporins, carbapenems, aminoglycosides, fluoroquinolones and phosphonic acids. In addition, our P. mirabilis SCDR1 isolate showed high resistance against colloidal and composite Nanosilver and metallic silver when compared to other tested Gram positive and negative bacterial species, both qualitatively and quantitatively. To the best of our knowledge, this is the first reported case of bacterial spontaneous resistance to colloidal and composite nanosilver. However, Gunawan et al., (2013) reported the occurrence of induced adaptation, of non-targeted environmental Bacillus species to antimicrobial Nanosilver [14]. In addition, it was found that bacteria can straightforwardly develop resistance to AgNPs, and this occurs by relatively simple genomic changes [54]. They both showed that a Bacillus sp. environmental isolate and an E.coli isolate were able to adapt to Nanosilver cytotoxicity upon continued exposure. Nonetheless, as previously stated, P. mirabilis SCDR1 exhibited instantaneous resistance against nanosilver without the need for any prolonged exposure. P. mirabilis SCDR1 demonstrated resistance against colloidal nanosilver assessed either by disk diffusion or by minimal inhibitory concentration methods. While all used concentrations of colloidal Nanosilver have shown strong effects on all tested microorganisms (Table 1), there was no effect on the bacterial growth of P. mirabilis SCDR1 even at the highest used concentration (200 ppm). Similarly, P. mirabilis SCDR1 was able to resist ten fold (500 ppm) higher than K. pneumoniae (50 ppm), five fold higher than P. aeruginosa and E. coli (100 ppm) and two and a half fold (200 ppm) higher than S. aureus and E. cloacae (Table 2). Moreover, while both laboratory prepared and commercially available silver and Nanosilver composite showed a clear effect against both S. aureus and P. aeruginosa, the most common pathogens of diabetic foot ulcer, not effect was observed against P. mirabilis SCDR1 (Table 3). Although chitosan nanosilver composites have documented combined effect against both Gram positive and negative pathogens [37] no effect was observed against P. mirabilis SCDR1. Silver is a highly toxic element for microbes. The Nanosilver exhibits high surface to volume ratio, which shows increased antimicrobial power in comparison to the same bulk silver material [55]. It is suggested that the antimicrobial mechanism of silver ions involves the disruption of phospholipids of cytoplasmic, and the disruption of DNA replication, impairing the function of ribosomes to transcribe messenger RNA and/or inactivation of cytochrome b by binding with sulfhydryl group [56]. P. mirabilis SCDR1 genome analysis showed that our isolate contains a large number of genes (245) responsible for xenobiotics biodegradation and metabolism (Additional file 2: Table S2). Although P. mirabilis SCDR1 does not contain the chitinase genes responsible for Chitin and chitosan degradation, it contained Chitin binding protein (cbp, 203 amino acid protein). This may justify the ability of P. mirabilis SCDR1 to resist the antimicrobial effect of chitosan. Chitin-binding protein even without any catalytic domain can facilitate the degradation of β-chitin by means of disrupting the crystalline chitin polymer structure [57, 58]. Microbial ability to produce proteins with high specific affinity to a certain crystalline chitin structure could be pivotal for the capability of bacteria to differentiate and react to specific crystalline chitin structures [59]. In addition, these chitin-binding domains may affect chitin degradation by facilitating adhesion of cells to the chitinous materials [57]. Thus, although we did not detect chitinase genes in P. mirabilis SCDR1, the presence of Chitin-binding protein suggests that P. mirabilis SCDR1 has some mechanisms of protection against chitin and the chitosan antimicrobial effect. In addition, the presence of genes encoding for the members Chitosanase family GH3 of N, N′-diacetylchitobiose-specific 6-phospho-beta-glucosidase (EC 3.2.1.86), Beta N-acetyl-glucosaminidase (nagZ, beta-hexosaminidase) (EC 3.2.1.52), and Glucan endo-1, 4-beta-glucosidase (EC 3.2.1.-) in P. mirabilis SCDR1 suggests that it can hydrolyze chitosan to glucosamine [6062]. This justifies the lack of antimicrobial effect of chitosan against P. mirabilis SCDR1. Likewise, P. mirabilis SCDR1 showed resistance against all the tested commercially available silver and Nanosilver containing wound dressing bandages. These silver containing commercially available bandages (wound dressing material) use different manufacturing technology and constituents. For example, Silvercel wound dressing contains high G calcium alginate in addition to 28% Silver-coated fibers (dressing contains 111 mg silver/100 cm2). The silver-coated fibers encompass elemental silver, which is converted to silver oxide upon contact with oxygen. Silver oxide dissolves in fluid and releases ionic silver (Ag+) that has antimicrobial action [63]. Clinical studies showed that Silvercel wound dressing is effective against many common wound pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin -resistant Staphylococcus epidermidis (MRSE) and vancomycin-resistant Enterococcus (VRE). In addition, these studies showed that Silvercel wound dressing prevented and disrupted the formation of bacterial biofilms [64, 65]. However, this was not the case with our P. mirabilis SCDR1 isolate. Similarly, Sorbsan Silver wound dressing which is made of the fiber of the calcium salt of the alginic acid that contains 1.5% silver [6668] did not show any antimicrobial effect against P. mirabilis SCDR1 isolate. Likewise, Colactive® Plus Ag, which is a silver impregnated collagen-based /alginate foam sheet wound dressing, did not show any antimicrobial effect against P. mirabilis SCDR1 isolate. In addition, Exsalt ®SD7 is a silver wound dressing that uses silver oxysalts technology. Silver oxysalts offer greater oxidation states of silver* (Ag2+, Ag3+) capable of interacting with microbial DNA, proteins and lipids, as well as providing potent oxidizing action through the increased power of Ag2+,3+ for advanced biocidal activity. Exsalt ®SD7 showed high antimicrobial activity against tested Gram-negative and positive bacteria and fungi tested [69]. P. mirabilis SCDR1 isolate showed high resistance against Exsalt ®SD7. In addition, P. mirabilis SCDR1 isolate showed high resistance against Puracol ® Plus Ag, which is made of 100% Collagens in addition to antimicrobial silver. Furthermore, Actisorb® Silver 220, which is a sterile primary dressing encompassing an activated charcoal cloth, impregnated with silver within a spun bonded perforated nylon sleeve [70] was not active against P. mirabilis SCDR1 isolate.
Pathogenomics analysis showed that P. mirabilis SCDR1 isolate is a potential virulent pathogen (Additional files 3 and 4: Tables 3 and 4). P. mirabilis SCDR1 shows that it possesses the characteristic bull’s eye pattern of swarming behavior. Presenting swarmer cells form is associated with the increase in expression of virulence genes [71]. Swarming is important to P. mirabilis uropathogenesis. It has been shown that swarming bacteria that move in multicellular groups exhibit adaptive resistance to multiple antibiotics [72]. Swarming behavior promotes the survival of bacteria in harsh environments or in unfavorable conditions. Moreover, migrating swarm cells display an increased resistance to many of antimicrobial agents. Therefore antimicrobial resistance could be a general feature of bacterial multicellular social behavior [73]. For example, the swarm cells of P. aeruginosa were able to migrate very close to the disc containing arsenite, indicating resistance to this heavy metal [73]. It has been suggested that high densities promote bacterial survival, the ability to move, as well as the speed of movement, confers an added advantage, making swarming an effective strategy for prevailing against antimicrobials including heavy metals [72, 73]. Furthermore, altruism or self-sacrifice is a suggested phenomenon associated with swarming, which involves risk of wiping out some individuals upon movement of bacteria to a different location, allowing the remaining individuals to continue their quest [72, 74]. Another suggested phenomenon associated with swarming is selfish behavior, in which the survival may be highest on top cells that are furthest from the antimicrobial agent while the lower cells in the swarm die because of the proximity to antimicrobial agents [72, 75]. Thus, selfish cells within the swarm sense where the best location is to avoid the toxic effect of the antimicrobial agent. Swarming behavior may indeed be one main reason for the observed nanosilver resistance of P. mirabilis SCDR1. Thus, maintaining high cell density, through the observed quorum sensing ability (Additional file 4: Table S4) and the circulation within the multilayered colony to minimize exposure to the heavy metal in addition to the death of individuals that are directly exposed, could be the key to the observed nanosilver resistance.
P. mirabilis SCDR1 isolate exhibited the ability of biofilm formation and also our pathogenomics analysis showed that it contains the genes responsible for this, such as glpC gene coding for anaerobic glycerol-3-phosphate dehydrogenase subunit C (EC 1.1.5.3), pmrI gene coding for UDP-glucuronic acid decarboxylase and baaS gene coding for biofilm formation regulatory protein BssS. We believe that the ability of P. mirabilis SCDR1 to form biofilm may also assist in the observed Nanosilver resistance. Biofilm formation can reduce the metal toxic effect by trapping it outside the cells. It was found that in the relative bacteria Proteus vulgaris XC 2, the biofilm cells showed considerably greater resistance to Chloromycetin compared to planktonic cells (free-floating counterparts) [76]. Moreover, it is suggested that the ability of biofilm formation may play a pivotal role in Polymyxin B antibiotic resistance in P. mirabilis [77]. Furthermore, it was found that biofilm formation is very important for heavy metal resistance in Pseudomonas sp. and that a biofilm lacking mutant was less tolerant to heavy metals [78]. Furthermore, it was found that both Extracellular Polysaccharides and Biofilm Formation is a resistance mechanism against toxic metals in Sinorhizobium meliloti, the nitrogen-fixing bacterium [79]. In addition, several reports claimed that the minimum inhibitory concentration (MIC) of some antibiotics for biofilms can be 1000-fold higher than that for planktonic bacteria [80].
It is well known that there are several mechanisms for metal resistance. These include physicochemical interactions, efflux, intracellular sequestration and extracellular precipitation by the excreted polymeric compounds [79]. Indeed, additional to swarming activity, Polysaccharides and biofilm formation (Additional file 4: Table S4), P. mirabilis SCDR1 contains several genes and proteins that also facilitate metal resistance including silver and Nanosilver (Table 8). Our results indicate the presence of endogenous silver and copper resistance mechanism in P. mirabilis SCDR1. We observed the presence of gene determinants of Copper/silver efflux system, oprB encoding for Copper/silver efflux system outer membrane protein CusC (outer membrane efflux protein OprB), oprM encoding for Copper/silver efflux system outer membrane protein CusC (outer membrane efflux protein OprM), cusC_1 encoding for Copper/silver efflux system outer membrane protein CusC (RND efflux system outer membrane lipoprotein), cpxA encoding for Copper sensory histidine kinase and outer membrane component of tripartite multidrug resistance system (CusC). In addition, we observed the presence of several Copper resistance genes/proteins were detected, namely, copA, copB, copC, copD, cueO, cueR, cutC, cutF and CuRO_2_CopA_like1. A similar endogenous silver and copper resistance mechanism has been described in E. coli and has been associated with the loss of porins from the outer membrane and up-regulation of the native Cus efflux mechanism, which is capable of transporting silver out of the cell [81, 82]. However, the genetic basis resistant phenotypes are still not fully known, and it is not known if they are obligatory or sufficient to exhibit resistance to silver [83]. Thus, we suggest a comprehensive study for this endogenous silver resistance mechanism within the Proteus mirabilis as well as E. coli.
Furthermore, we observed the presence of genes encoding to enzymes involved in heavy metal resistance such as Glutathione S-transferase (EC 2.5.1.18) (gst1, gst, Delta and Uncharacterized) in P. mirabilis SCDR1 genome. Thus, we propose a role of Glutathione S-transferases of P. mirabilis SCDR1 in the observed Nanosilver resistance. Glutathione S-transferases (GSTs) are a family of multifunctional proteins that play an important role in the detoxification of harmful physiological and xenobiotic compounds in organisms [84]. Moreover, it was found that a Glutathione S-transferase is involved in copper, cadmium, Lead and mercury resistance [85]. Furthermore, it was found that GST genes are differentially expressed in defense against oxidative stress caused by Cd and Nanosilver exposure [85].
Moreover, we observed the presence of a complete tellurite resistance operon (terB, terA, terC, terD, terE, terZ) which was suggested as contributing to virulence or fitness and protection from other forms of oxidative stress or agents causing membrane damage, such as silver and Nanosilver, in P. mirabilis [86]. Several other heavy metal resistance genes and proteins were observed in the P. mirabilis SCDR1 genome. These included arsM encoding for arsenite S-adenosylmethyltransferase (Methyltransferase type 11), which play an important role in prokaryotic resistance and detoxification mechanism to arsenite [87, 88] and merB encoding for alkylmercury lyase that cleaves the carbon-mercury bond of organomercurials, such as phenylmercuric acetate [89]. Moreover, numerous heavy metal resistance proteins were observed, such as magnesium/cobalt efflux protein CorC, metal resistance proteins, nickel-cobalt-cadmium resistance protein NccB, arsenical pump membrane protein (ArsB permease), Lead, cadmium, zinc and mercury transporting ATPase (Table 8).
In order to gain information about antimicrobial resistome constituents in P. mirabilis species, we performed comparative genomics analysis amongst all available 56 P. mirabilis genomes, including the P. mirabilis SCDR1 genome. As stated before, all P. mirabilis genomes shared 16 AMROs (Table 6). For example, all genomes contained the AMRO of copper sensory histidine kinase CpxA in cpxA mutant confer resistant to amikacin, copper-sensing two-component system response regulator CpxR, which is a regulator that promotes acrD expression when phosphorylated by a cascade involving CpxA, a sensor kinase and linked to cefepime and chloramphenicol resistance in Klebsiella pneumoniae [90]. However, different P. mirabilis genomes varied in the remaining 45 studied AMRO (Table 6). For example, genomics analysis of P. mirabilis-SCDR1 showed that our isolates contained genetic determinants for fluoroquinolones resistance (gyrA, parC and parE) [91, 92], Daptomycin and Rifamycin resistance (rpoB) [93], Chloramphenicol (cpxR, cpxA and cat) [90, 94], Ethidium bromide-methyl viologen resistance protein (emrE) [95] and Polymyxin and colistin resistance (phoP) [96]. In addition, several multidrug resistance efflux systems and complexes were observed. These include MdtABC-TolC, which is a multidrug efflux system in Gram-negative bacteria, including E. coli and Salmonella that confer resistance against β-lactams, novobiocin and deoxycholate. It is noteworthy that MdtABC-TolC and AcrD plays a role in metal resistance (copper and zinc), along with their BaeSR regulatory system [97] which was also was found in our P. mirabilis SCDR1 genome [Table 7], and thus may also play an additional role in silver resistance. MdtABC-TolC contains MdtA, which is a membrane fusion protein, TolC, which is the outer membrane channel and MdtBC that forms a drug transporter. In the absence of MdtB, the MdtAC-TolC has narrower drug specificity, leading to the loss of novobiocin resistance [98]. The MdtABC and AcrD systems may be related to bacterial metal homeostasis by transporting metals directly. This is to some extent similar to the copper and silver resistance mechanism by cation efflux of the CusABC system belonging to the RND protein superfamily [97, 99].
As stated before, this is the first report for spontaneous resistance against nanosilver. However, Gunawan et al., (2013) reported the natural ability of Bacillus sp. to adapt to nanosilver cytotoxicity under prolonged cellular oxidative stress stimulation through the nanoparticles incubation [14]. They found that the induced effects of adaptation continued even after discontinuation of nanosilver exposure. They also suggested that this characteristic ability of the ubiquitously-occurring Bacillus sp. may pose adversative consequences to the extensive use of nanosilver. Moreover, Graves et al., (2015) showed that after 225 generations of the treatment with nanosilver, the treated E. coli populations demonstrated greater fitness compared with control strains in the presence of silver nanoparticles [54]. We could also have suggested that the observed P. mirabilis SCDR1 nanosilver resistance might be an adaptive effect of the use of silver containing bandages in the Diabetic foot ulcer clinic. However, the reference strain P. mirabilis ATCC 29906 (isolated from urogenital tract of Homo sapiens) also showed resistance against colloidal nanosilver. In addition, it seems that nanosilver resistance is a widespread character in P. mirabilis species, since all other tested 50 isolates showed resistance against colloidal nanosilver [unpublished data]. Comparative metal resistance in P. mirabilis genomes contains some of the genetics determinants that can aid in nanosilver/silver resistance [unpublished data]. However, this conclusion needs to be further tested in a larger number of P. mirabilis isolated from different infection sites and geographical locations.
Increasing antimicrobial nanosilver usage could prompt a silver resistance problem in Gram-negative pathogens, particularly since silver resistance is already known to exist in several such species [81, 100]. Both exogenous (horizontally acquired Sil system) endogenous (mutational Cus system) resistance to silver has been reported in Gram-negative bacteria [13, 81]. Li et al. [81] selected five Escherichia coli mutants that present a ≥ 64-fold decreases in silver susceptibility compared with their original strain. All the mutants exhibited loss of expression of outer membrane porins (OmpF or OmpF/C), which seemingly resulted in the reduction of outer membrane permeability. These findings implied that reduced silver susceptibility is a result of restricting silver entrance into the bacterial cell. Moreover, they found that these mutants express active efflux that pumps silver outside of the cell. It was found that the cus CFBA operon is the responsible of silver efflux pump. Similarly, in our case, we observed the presence of resistance operon with high similarity to the cus operon, which is a chromosomally encoded system because of the lack of any plasmid in P. mirabilis SCDR1. However, both endogenous and exogenous silver resistance systems, in Gram-negative bacteria, remain incompletely understood [83].
The occurrence of induced nanosilver resistance (in vitro) in Bacillus sp. and E. coli [14, 54], spontaneous resistance (in our case) and the frequent uses and misuses of nanosilver-containing medical products should suggest adopting an enhanced surveillance systems for nanosilver-resistant isolates in medical setups. In addition, there should be greater control over utilizing nanosilver-containing products in order to maintain nanosilver as a valuable alternative approach in the fight against multidrug resistant pathogens.

Conclusion

In the present study, we introduced the P. mirabilis SCDR1 isolate that was collected from a diabetic ulcer patient. P. mirabilis SCDR1 showed high levels of resistance against nanosilver colloids, nanosilver chitosan composite and the commercially available nanosilver and silver bandages. Our isolate contains all the required pathogenicity and virulence factors to establish a successful infection. P. mirabilis SCDR1 contains several physical and biochemical mechanisms for antibiotics and silver/nanosilver resistance, which are biofilm formation, swarming mobility, efflux systems, and enzymatic detoxification.

Acknowledgements

The authors want to thank the members of the Diabeticfoot unit in the University Diabetes Center at King Saud University for their help in collecting the bacteria samples. Furthermore, we want to thanks the members of the nanotechnology department in SCDR for providing the chitosan nanosilver composites. In addition we want to acknowledge that NGS experiments and analysis were supported by the Saudi Human Genome Program (SHGP) at KACST and KFSHRC. Moreover, we want to thank Dr. Rebecca Wattam, form the Biocomplexity Institute at Virginia Polytechnic Institute and State University, for her great assistance during data analysis using PATRIC services and tools.

Funding

The authors received internal research fund from King Faisal specialist hospital and research center to support the publication.

Availability of data and materials

Data from our draft genome of P. mirabilis SCDR1 isolate was deposited in NCBI-GenBank with an accession number LUFT00000000.
This study was approved by institutional review board in King Saud University, Collage of Medicine Riyadh, Kingdom of Saudi Arabia. The subject was provided written informed consent for participating in this study.
All authors have consented for publication of this manuscript.

Competing interests

The authors declare that they have no competing interests

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett. 2008;176:1–12.CrossRefPubMed Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett. 2008;176:1–12.CrossRefPubMed
2.
Zurück zum Zitat Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns J. Int. Soc. Burn Inj 2004;30 Suppl 1:S1–9. Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns J. Int. Soc. Burn Inj 2004;30 Suppl 1:S1–9.
3.
Zurück zum Zitat Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, et al. Silver nanoparticles as potential antibacterial agents. Mol. Basel Switz. 2015;20:8856–74. Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, et al. Silver nanoparticles as potential antibacterial agents. Mol. Basel Switz. 2015;20:8856–74.
4.
Zurück zum Zitat Lu L, Sun RW-Y, Chen R, Hui C-K, Ho C-M, Luk JM, et al. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther. 2008;13:253–62.PubMed Lu L, Sun RW-Y, Chen R, Hui C-K, Ho C-M, Luk JM, et al. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther. 2008;13:253–62.PubMed
6.
Zurück zum Zitat Oyanedel-Craver VA, Smith JA. Sustainable colloidal-silver-impregnated ceramic filter for point-of-use water treatment. Environ Sci Technol. 2008;42:927–33.CrossRefPubMed Oyanedel-Craver VA, Smith JA. Sustainable colloidal-silver-impregnated ceramic filter for point-of-use water treatment. Environ Sci Technol. 2008;42:927–33.CrossRefPubMed
7.
Zurück zum Zitat Prabhu S, Poulose EK. Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. Int. Nano Lett. 2012;2:32.CrossRef Prabhu S, Poulose EK. Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. Int. Nano Lett. 2012;2:32.CrossRef
8.
Zurück zum Zitat Samuel U, Guggenbichler JP. Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. Int J Antimicrob Agents. 2004;23(Suppl 1):S75–8.CrossRefPubMed Samuel U, Guggenbichler JP. Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. Int J Antimicrob Agents. 2004;23(Suppl 1):S75–8.CrossRefPubMed
9.
Zurück zum Zitat Saeb ATM, Alshammari AS, Al-Brahim H, Al-Rubeaan KA. Production of silver nanoparticles with strong and stable antimicrobial activity against highly pathogenic and multidrug resistant bacteria. ScientificWorldJournal. 2014;2014:704708.CrossRefPubMedPubMedCentral Saeb ATM, Alshammari AS, Al-Brahim H, Al-Rubeaan KA. Production of silver nanoparticles with strong and stable antimicrobial activity against highly pathogenic and multidrug resistant bacteria. ScientificWorldJournal. 2014;2014:704708.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Velázquez-Velázquez JL, Santos-Flores A, Araujo-Meléndez J, Sánchez-Sánchez R, Velasquillo C, González C, et al. Anti-biofilm and cytotoxicity activity of impregnated dressings with silver nanoparticles. Mater Sci Eng C Mater Biol Appl. 2015;49:604–11.CrossRefPubMed Velázquez-Velázquez JL, Santos-Flores A, Araujo-Meléndez J, Sánchez-Sánchez R, Velasquillo C, González C, et al. Anti-biofilm and cytotoxicity activity of impregnated dressings with silver nanoparticles. Mater Sci Eng C Mater Biol Appl. 2015;49:604–11.CrossRefPubMed
11.
Zurück zum Zitat Lullove EJ, Bernstein B. Use of SilvrSTAT® in lower extremity wounds: a two center case series « Journal of Diabetic Foot Complications 2015;7:13–16. Lullove EJ, Bernstein B. Use of SilvrSTAT® in lower extremity wounds: a two center case series « Journal of Diabetic Foot Complications 2015;7:13–16.
12.
Zurück zum Zitat Hendry AT, Stewart IO. Silver-resistant Enterobacteriaceae from hospital patients. Can J Microbiol. 1979;25:915–21.CrossRefPubMed Hendry AT, Stewart IO. Silver-resistant Enterobacteriaceae from hospital patients. Can J Microbiol. 1979;25:915–21.CrossRefPubMed
13.
Zurück zum Zitat McHugh GL, Moellering RC, Hopkins CC, Swartz MN. Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet Lond Engl. 1975;1:235–40.CrossRef McHugh GL, Moellering RC, Hopkins CC, Swartz MN. Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet Lond Engl. 1975;1:235–40.CrossRef
14.
Zurück zum Zitat Gunawan C, Teoh WY, Marquis CP. Amal R. Induced adaptation of Bacillus sp to antimicrobial nanosilver Small Weinh Bergstr Ger. 2013;9:3554–60. Gunawan C, Teoh WY, Marquis CP. Amal R. Induced adaptation of Bacillus sp to antimicrobial nanosilver Small Weinh Bergstr Ger. 2013;9:3554–60.
15.
Zurück zum Zitat Jansen AM, Lockatell CV, Johnson DE, Mobley HLT. Visualization of Proteus Mirabilis morphotypes in the urinary tract: the elongated swarmer cell is rarely observed in ascending urinary tract infection. Infect Immun. 2003;71:3607–13.CrossRefPubMedPubMedCentral Jansen AM, Lockatell CV, Johnson DE, Mobley HLT. Visualization of Proteus Mirabilis morphotypes in the urinary tract: the elongated swarmer cell is rarely observed in ascending urinary tract infection. Infect Immun. 2003;71:3607–13.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Mobley HL, Belas R. Swarming and pathogenicity of Proteus Mirabilis in the urinary tract. Trends Microbiol. 1995;3:280–4.CrossRefPubMed Mobley HL, Belas R. Swarming and pathogenicity of Proteus Mirabilis in the urinary tract. Trends Microbiol. 1995;3:280–4.CrossRefPubMed
17.
Zurück zum Zitat Mathur S, Sabbuba NA, Suller MTE, Stickler DJ, Feneley RCL. Genotyping of urinary and fecal Proteus Mirabilis isolates from individuals with long-term urinary catheters. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2005;24:643–4.CrossRef Mathur S, Sabbuba NA, Suller MTE, Stickler DJ, Feneley RCL. Genotyping of urinary and fecal Proteus Mirabilis isolates from individuals with long-term urinary catheters. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2005;24:643–4.CrossRef
18.
19.
Zurück zum Zitat Armbruster CE, Mobley HLT. Merging mythology and morphology: the multifaceted lifestyle of Proteus Mirabilis. Nat Rev Microbiol. 2012;10:743–54.CrossRefPubMedPubMedCentral Armbruster CE, Mobley HLT. Merging mythology and morphology: the multifaceted lifestyle of Proteus Mirabilis. Nat Rev Microbiol. 2012;10:743–54.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Jacobsen SM, Stickler DJ, Mobley HLT, Shirtliff ME. Complicated catheter-associated urinary tract infections due to Escherichia Coli and Proteus Mirabilis. Clin Microbiol Rev. 2008;21:26–59.CrossRefPubMedPubMedCentral Jacobsen SM, Stickler DJ, Mobley HLT, Shirtliff ME. Complicated catheter-associated urinary tract infections due to Escherichia Coli and Proteus Mirabilis. Clin Microbiol Rev. 2008;21:26–59.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Rózalski A, Sidorczyk Z, Kotełko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev MMBR. 1997;61:65–89.PubMed Rózalski A, Sidorczyk Z, Kotełko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev MMBR. 1997;61:65–89.PubMed
24.
Zurück zum Zitat Pearson MM, Sebaihia M, Churcher C, Quail MA, Seshasayee AS, Luscombe NM, et al. Complete genome sequence of uropathogenic Proteus Mirabilis, a master of both adherence and motility. J Bacteriol. 2008;190:4027–37.CrossRefPubMedPubMedCentral Pearson MM, Sebaihia M, Churcher C, Quail MA, Seshasayee AS, Luscombe NM, et al. Complete genome sequence of uropathogenic Proteus Mirabilis, a master of both adherence and motility. J Bacteriol. 2008;190:4027–37.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Habibi M, Asadi Karam MR, Bouzari S. In silico design of fusion protein of FimH from uropathogenic Escherichia Coli and MrpH from Proteus Mirabilis against urinary tract infections. Adv. Biomed Res. 2015;4:217.PubMedPubMedCentral Habibi M, Asadi Karam MR, Bouzari S. In silico design of fusion protein of FimH from uropathogenic Escherichia Coli and MrpH from Proteus Mirabilis against urinary tract infections. Adv. Biomed Res. 2015;4:217.PubMedPubMedCentral
26.
Zurück zum Zitat Baldo C, Rocha SPD. Virulence factors of Uropathogenic Proteus Mirabilis - a mini review. Int. J. Technol. Enhanc. Emerg. Eng. Res. 2014;3:24–7. Baldo C, Rocha SPD. Virulence factors of Uropathogenic Proteus Mirabilis - a mini review. Int. J. Technol. Enhanc. Emerg. Eng. Res. 2014;3:24–7.
27.
Zurück zum Zitat Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol. 2010;13:558–64.CrossRefPubMed Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol. 2010;13:558–64.CrossRefPubMed
29.
Zurück zum Zitat Horner CS, Abberley N, Denton M, Wilcox MH. Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010-2012. Epidemiol Infect. 2014;142:399–403.CrossRefPubMed Horner CS, Abberley N, Denton M, Wilcox MH. Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010-2012. Epidemiol Infect. 2014;142:399–403.CrossRefPubMed
30.
Zurück zum Zitat Miró E, Agüero J, Larrosa MN, Fernández A, Conejo MC, Bou G, et al. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2013;32:253–9.CrossRef Miró E, Agüero J, Larrosa MN, Fernández A, Conejo MC, Bou G, et al. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2013;32:253–9.CrossRef
31.
Zurück zum Zitat Sheng W-H, Badal RE, Hsueh P-R, Program SMART. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother. 2013;57:2981–8.CrossRefPubMedPubMedCentral Sheng W-H, Badal RE, Hsueh P-R, Program SMART. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother. 2013;57:2981–8.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther. 2013;35:872–7.CrossRefPubMed Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther. 2013;35:872–7.CrossRefPubMed
33.
Zurück zum Zitat Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, et al. Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011. J Inf Secur. 2014;68:71–6. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, et al. Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011. J Inf Secur. 2014;68:71–6.
34.
Zurück zum Zitat Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Walkty AJ, Hoban DJ, et al. Vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother. 2013;57:5600–11.CrossRefPubMedPubMedCentral Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Walkty AJ, Hoban DJ, et al. Vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother. 2013;57:5600–11.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014;78:443–8.CrossRefPubMed Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014;78:443–8.CrossRefPubMed
36.
Zurück zum Zitat Chen L, Al Laham N, Chavda KD, Mediavilla JR, Jacobs MR, Bonomo RA, et al. First report of an OXA-48-producing multidrug-resistant Proteus Mirabilis strain from Gaza, Palestine. Antimicrob Agents Chemother. 2015;59:4305–7.CrossRefPubMedPubMedCentral Chen L, Al Laham N, Chavda KD, Mediavilla JR, Jacobs MR, Bonomo RA, et al. First report of an OXA-48-producing multidrug-resistant Proteus Mirabilis strain from Gaza, Palestine. Antimicrob Agents Chemother. 2015;59:4305–7.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Latif U, Al-Rubeaan K, Saeb ATM. A review on antimicrobial chitosan-silver nanocomposites: a roadmap toward pathogen targeted synthesis. Int J Polym Mater Polym Biomater. 2015;64:448–58.CrossRef Latif U, Al-Rubeaan K, Saeb ATM. A review on antimicrobial chitosan-silver nanocomposites: a roadmap toward pathogen targeted synthesis. Int J Polym Mater Polym Biomater. 2015;64:448–58.CrossRef
38.
Zurück zum Zitat Matuschek E, Brown DFJ, Kahlmeter G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect Dis. 2014;20:O255–66. Matuschek E, Brown DFJ, Kahlmeter G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect Dis. 2014;20:O255–66.
39.
Zurück zum Zitat Holla G, Yeluri R, Munshi AK. Evaluation of minimum inhibitory and minimum bactericidal concentration of nano-silver base inorganic anti-microbial agent (Novaron(®)) against streptococcus mutans. Contemp. Clin Dent. 2012;3:288–93.CrossRefPubMedPubMedCentral Holla G, Yeluri R, Munshi AK. Evaluation of minimum inhibitory and minimum bactericidal concentration of nano-silver base inorganic anti-microbial agent (Novaron(®)) against streptococcus mutans. Contemp. Clin Dent. 2012;3:288–93.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Yassien M, Khardori N. Interaction between biofilms formed by Staphylococcus Epidermidis and quinolones. Diagn Microbiol Infect Dis. 2001;40:79–89.CrossRefPubMed Yassien M, Khardori N. Interaction between biofilms formed by Staphylococcus Epidermidis and quinolones. Diagn Microbiol Infect Dis. 2001;40:79–89.CrossRefPubMed
42.
Zurück zum Zitat Darling ACE, Mau B, Blattner FR, Perna NT. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res. 2004;14:1394–403.CrossRefPubMedPubMedCentral Darling ACE, Mau B, Blattner FR, Perna NT. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res. 2004;14:1394–403.CrossRefPubMedPubMedCentral
43.
44.
Zurück zum Zitat Wattam AR, Abraham D, Dalay O, Disz TL, Driscoll T, Gabbard JL, et al. PATRIC, the bacterial bioinformatics database and analysis resource. Nucleic Acids Res. 2014;42:D581–91.CrossRefPubMed Wattam AR, Abraham D, Dalay O, Disz TL, Driscoll T, Gabbard JL, et al. PATRIC, the bacterial bioinformatics database and analysis resource. Nucleic Acids Res. 2014;42:D581–91.CrossRefPubMed
45.
Zurück zum Zitat Cosentino S, Voldby Larsen M, Møller Aarestrup F, Lund O. PathogenFinder--distinguishing friend from foe using bacterial whole genome sequence data. PLoS One. 2013;8:e77302.CrossRefPubMedPubMedCentral Cosentino S, Voldby Larsen M, Møller Aarestrup F, Lund O. PathogenFinder--distinguishing friend from foe using bacterial whole genome sequence data. PLoS One. 2013;8:e77302.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Liu B, Pop M. ARDB--antibiotic resistance genes database. Nucleic Acids Res. 2009;37:D443–7.CrossRefPubMed Liu B, Pop M. ARDB--antibiotic resistance genes database. Nucleic Acids Res. 2009;37:D443–7.CrossRefPubMed
48.
Zurück zum Zitat McArthur AG, Wright GD. Bioinformatics of antimicrobial resistance in the age of molecular epidemiology. Curr Opin Microbiol. 2015;27:45–50.CrossRefPubMed McArthur AG, Wright GD. Bioinformatics of antimicrobial resistance in the age of molecular epidemiology. Curr Opin Microbiol. 2015;27:45–50.CrossRefPubMed
49.
Zurück zum Zitat McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The comprehensive antibiotic resistance database. Antimicrob Agents Chemother. 2013;57:3348–57.CrossRefPubMedPubMedCentral McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The comprehensive antibiotic resistance database. Antimicrob Agents Chemother. 2013;57:3348–57.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67:2640–4.CrossRefPubMedPubMedCentral Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67:2640–4.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Pal C, Bengtsson-Palme J, Rensing C, Kristiansson E, Larsson DGJ. BacMet: antibacterial biocide and metal resistance genes database. Nucleic Acids Res. 2014;42:D737–43.CrossRefPubMed Pal C, Bengtsson-Palme J, Rensing C, Kristiansson E, Larsson DGJ. BacMet: antibacterial biocide and metal resistance genes database. Nucleic Acids Res. 2014;42:D737–43.CrossRefPubMed
52.
Zurück zum Zitat Olaitan AO, Morand S, Rolain J-M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643.CrossRefPubMedPubMedCentral Olaitan AO, Morand S, Rolain J-M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2012;18:268–81. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2012;18:268–81.
55.
Zurück zum Zitat Tang Z, Liu S, Dong S, Wang E. Electrochemical synthesis of ag nanoparticles on functional carbon surfaces. J Electroanal Chem. 502:146–51. Tang Z, Liu S, Dong S, Wang E. Electrochemical synthesis of ag nanoparticles on functional carbon surfaces. J Electroanal Chem. 502:146–51.
56.
Zurück zum Zitat Park H-J, Kim JY, Kim J, Lee J-H, Hahn J-S, MB G, et al. Silver-ion-mediated reactive oxygen species generation affecting bactericidal activity. Water Res. 2009;43:1027–32.CrossRefPubMed Park H-J, Kim JY, Kim J, Lee J-H, Hahn J-S, MB G, et al. Silver-ion-mediated reactive oxygen species generation affecting bactericidal activity. Water Res. 2009;43:1027–32.CrossRefPubMed
58.
Zurück zum Zitat Vaaje-Kolstad G, Horn SJ, van Aalten DMF, Synstad B, Eijsink VGH. The non-catalytic chitin-binding protein CBP21 from Serratia Marcescens is essential for chitin degradation. J Biol Chem. 2005;280:28492–7.CrossRefPubMed Vaaje-Kolstad G, Horn SJ, van Aalten DMF, Synstad B, Eijsink VGH. The non-catalytic chitin-binding protein CBP21 from Serratia Marcescens is essential for chitin degradation. J Biol Chem. 2005;280:28492–7.CrossRefPubMed
59.
Zurück zum Zitat Svitil AL, Chadhain S, Moore JA, Kirchman DL. Chitin degradation proteins produced by the marine bacterium Vibrio Harveyi growing on different forms of chitin. Appl Environ Microbiol. 1997;63:408–13.PubMedPubMedCentral Svitil AL, Chadhain S, Moore JA, Kirchman DL. Chitin degradation proteins produced by the marine bacterium Vibrio Harveyi growing on different forms of chitin. Appl Environ Microbiol. 1997;63:408–13.PubMedPubMedCentral
60.
Zurück zum Zitat Wieczorek AS, Hetz SA, Kolb S. Microbial responses to chitin and chitosan in oxic and anoxic agricultural soil slurries. Biogeosciences. 2014;11:3339–52.CrossRef Wieczorek AS, Hetz SA, Kolb S. Microbial responses to chitin and chitosan in oxic and anoxic agricultural soil slurries. Biogeosciences. 2014;11:3339–52.CrossRef
61.
Zurück zum Zitat Gupta V, Prasanna R, Natarajan C, Srivastava AK, Sharma J. Identification, characterization, and regulation of a novel antifungal chitosanase gene (cho) in anabaena spp. Appl Environ Microbiol. 2010;76:2769–77.CrossRefPubMedPubMedCentral Gupta V, Prasanna R, Natarajan C, Srivastava AK, Sharma J. Identification, characterization, and regulation of a novel antifungal chitosanase gene (cho) in anabaena spp. Appl Environ Microbiol. 2010;76:2769–77.CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Gupta V, Prasanna R, Srivastava AK, Sharma J. Purification and characterization of a novel antifungal endo-type chitosanase from anabaena fertilissima. Ann Microbiol. 2011;62:1089–98.CrossRef Gupta V, Prasanna R, Srivastava AK, Sharma J. Purification and characterization of a novel antifungal endo-type chitosanase from anabaena fertilissima. Ann Microbiol. 2011;62:1089–98.CrossRef
63.
Zurück zum Zitat Cutting K, White R, Edmonds M. The safety and efficacy of dressings with silver - addressing clinical concerns. Int Wound J. 2007;4:177–84.CrossRefPubMed Cutting K, White R, Edmonds M. The safety and efficacy of dressings with silver - addressing clinical concerns. Int Wound J. 2007;4:177–84.CrossRefPubMed
65.
Zurück zum Zitat Stephens S, Clark R, Del Bono M, Snyder R. Designing in vitro, in vivo and clinical evaluations to meet the needs of the patient and clinician: dressing wound adherence. Geneva; 2010. Stephens S, Clark R, Del Bono M, Snyder R. Designing in vitro, in vivo and clinical evaluations to meet the needs of the patient and clinician: dressing wound adherence. Geneva; 2010.
66.
Zurück zum Zitat Thomas S. Alginate dressings in surgery and wound management--part 1. J Wound Care. 2000;9:56–60.CrossRefPubMed Thomas S. Alginate dressings in surgery and wound management--part 1. J Wound Care. 2000;9:56–60.CrossRefPubMed
67.
Zurück zum Zitat Thomas S. Alginate dressings in surgery and wound management: part 2. J Wound Care. 2000;9:115–9.CrossRefPubMed Thomas S. Alginate dressings in surgery and wound management: part 2. J Wound Care. 2000;9:115–9.CrossRefPubMed
68.
Zurück zum Zitat Thomas S. Alginate dressings in surgery and wound management: part 3. J Wound Care. 2000;9:163–6.CrossRefPubMed Thomas S. Alginate dressings in surgery and wound management: part 3. J Wound Care. 2000;9:163–6.CrossRefPubMed
70.
Zurück zum Zitat Haycocks S, Chadwick P. Using an activated charcoal dressing with silver for malodour, infection and overgranulation in diabetic foot ulcers importance of appropriate dressing selection for diabetic foot ulcers. Diabet Foot J. 2014;17:74–7. Haycocks S, Chadwick P. Using an activated charcoal dressing with silver for malodour, infection and overgranulation in diabetic foot ulcers importance of appropriate dressing selection for diabetic foot ulcers. Diabet Foot J. 2014;17:74–7.
71.
Zurück zum Zitat Allison C, Lai HC, Hughes C. Co-ordinate expression of virulence genes during swarm-cell differentiation and population migration of Proteus Mirabilis. Mol Microbiol. 1992;6:1583–91.CrossRefPubMed Allison C, Lai HC, Hughes C. Co-ordinate expression of virulence genes during swarm-cell differentiation and population migration of Proteus Mirabilis. Mol Microbiol. 1992;6:1583–91.CrossRefPubMed
72.
Zurück zum Zitat Butler MT, Wang Q, Harshey RM. Cell density and mobility protect swarming bacteria against antibiotics. Proc Natl Acad Sci U S A. 2010;107:3776–81.CrossRefPubMedPubMedCentral Butler MT, Wang Q, Harshey RM. Cell density and mobility protect swarming bacteria against antibiotics. Proc Natl Acad Sci U S A. 2010;107:3776–81.CrossRefPubMedPubMedCentral
73.
Zurück zum Zitat Lai S, Tremblay J, Déziel E. Swarming motility: a multicellular behaviour conferring antimicrobial resistance. Environ Microbiol. 2009;11:126–36.CrossRefPubMed Lai S, Tremblay J, Déziel E. Swarming motility: a multicellular behaviour conferring antimicrobial resistance. Environ Microbiol. 2009;11:126–36.CrossRefPubMed
76.
Zurück zum Zitat Wu YL, Liu KS, Yin XT, Fei RM. GlpC gene is responsible for biofilm formation and defense against phagocytes and imparts tolerance to pH and organic solvents in Proteus vulgaris. Genet Mol Res GMR. 2015;14:10619–29.CrossRefPubMed Wu YL, Liu KS, Yin XT, Fei RM. GlpC gene is responsible for biofilm formation and defense against phagocytes and imparts tolerance to pH and organic solvents in Proteus vulgaris. Genet Mol Res GMR. 2015;14:10619–29.CrossRefPubMed
77.
Zurück zum Zitat Jiang S-S, Liu M-C, Teng L-J, Wang W-B, Hsueh P-R, Liaw S-J. Proteus Mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion. Antimicrob Agents Chemother. 2010;54:1564–71.CrossRefPubMedPubMedCentral Jiang S-S, Liu M-C, Teng L-J, Wang W-B, Hsueh P-R, Liaw S-J. Proteus Mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion. Antimicrob Agents Chemother. 2010;54:1564–71.CrossRefPubMedPubMedCentral
78.
Zurück zum Zitat Chien C-C, Lin B-C, Biofilm WC-H. Formation and heavy metal resistance by an environmental pseudomonas sp. Biochem Eng J. 2013;78:132–7.CrossRef Chien C-C, Lin B-C, Biofilm WC-H. Formation and heavy metal resistance by an environmental pseudomonas sp. Biochem Eng J. 2013;78:132–7.CrossRef
79.
Zurück zum Zitat Nocelli N, Bogino PC, Banchio E, Giordano W. Roles of extracellular polysaccharides and biofilm formation in heavy metal resistance of rhizobia. Materials. 2016;9:418.CrossRefPubMedCentral Nocelli N, Bogino PC, Banchio E, Giordano W. Roles of extracellular polysaccharides and biofilm formation in heavy metal resistance of rhizobia. Materials. 2016;9:418.CrossRefPubMedCentral
80.
Zurück zum Zitat Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–32.CrossRefPubMed Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–32.CrossRefPubMed
81.
Zurück zum Zitat Li XZ, Nikaido H, Williams KE. Silver-resistant mutants of Escherichia Coli display active efflux of ag+ and are deficient in porins. J Bacteriol. 1997;179:6127–32.CrossRefPubMedPubMedCentral Li XZ, Nikaido H, Williams KE. Silver-resistant mutants of Escherichia Coli display active efflux of ag+ and are deficient in porins. J Bacteriol. 1997;179:6127–32.CrossRefPubMedPubMedCentral
82.
Zurück zum Zitat Lok C-N, Ho C-M, Chen R, Tam PK-H, Chiu J-F, Che C-M. Proteomic identification of the Cus system as a major determinant of constitutive Escherichia Coli Silver resistance of chromosomal origin. J Proteome Res. 2008;7:2351–6.CrossRefPubMed Lok C-N, Ho C-M, Chen R, Tam PK-H, Chiu J-F, Che C-M. Proteomic identification of the Cus system as a major determinant of constitutive Escherichia Coli Silver resistance of chromosomal origin. J Proteome Res. 2008;7:2351–6.CrossRefPubMed
83.
Zurück zum Zitat Randall CP, Gupta A, Jackson N, Busse D, O’Neill AJ. Silver resistance in gram-negative bacteria: a dissection of endogenous and exogenous mechanisms. J Antimicrob Chemother. 2015;70:1037–46.PubMedPubMedCentral Randall CP, Gupta A, Jackson N, Busse D, O’Neill AJ. Silver resistance in gram-negative bacteria: a dissection of endogenous and exogenous mechanisms. J Antimicrob Chemother. 2015;70:1037–46.PubMedPubMedCentral
84.
Zurück zum Zitat Zhang W, Yin K, Li B, Chen LA. Glutathione S-transferase from Proteus Mirabilis involved in heavy metal resistance and its potential application in removal of Hg2+. J Hazard Mater. 2013;261:646–52.CrossRefPubMed Zhang W, Yin K, Li B, Chen LA. Glutathione S-transferase from Proteus Mirabilis involved in heavy metal resistance and its potential application in removal of Hg2+. J Hazard Mater. 2013;261:646–52.CrossRefPubMed
85.
Zurück zum Zitat Nair PMG, Choi J. Identification, characterization and expression profiles of Chironomus Riparius glutathione S-transferase (GST) genes in response to cadmium and silver nanoparticles exposure. Aquat Toxicol Amst Neth. 2011;101:550–60.CrossRef Nair PMG, Choi J. Identification, characterization and expression profiles of Chironomus Riparius glutathione S-transferase (GST) genes in response to cadmium and silver nanoparticles exposure. Aquat Toxicol Amst Neth. 2011;101:550–60.CrossRef
86.
Zurück zum Zitat Toptchieva A, Sisson G, Bryden LJ, Taylor DE, Hoffman PS. An inducible tellurite-resistance operon in Proteus Mirabilis. Microbiol Read Engl. 2003;149:1285–95.CrossRef Toptchieva A, Sisson G, Bryden LJ, Taylor DE, Hoffman PS. An inducible tellurite-resistance operon in Proteus Mirabilis. Microbiol Read Engl. 2003;149:1285–95.CrossRef
87.
Zurück zum Zitat Qin J, Lehr CR, Yuan C, Le XC, McDermott TR, Rosen BP. Biotransformation of arsenic by a Yellowstone thermoacidophilic eukaryotic alga. Proc Natl Acad Sci U S A. 2009;106:5213–7.CrossRefPubMedPubMedCentral Qin J, Lehr CR, Yuan C, Le XC, McDermott TR, Rosen BP. Biotransformation of arsenic by a Yellowstone thermoacidophilic eukaryotic alga. Proc Natl Acad Sci U S A. 2009;106:5213–7.CrossRefPubMedPubMedCentral
88.
Zurück zum Zitat Qin J, Rosen BP, Zhang Y, Wang G, Franke S, Rensing C. Arsenic detoxification and evolution of trimethylarsine gas by a microbial arsenite S-adenosylmethionine methyltransferase. Proc Natl Acad Sci U S A. 2006;103:2075–80.CrossRefPubMedPubMedCentral Qin J, Rosen BP, Zhang Y, Wang G, Franke S, Rensing C. Arsenic detoxification and evolution of trimethylarsine gas by a microbial arsenite S-adenosylmethionine methyltransferase. Proc Natl Acad Sci U S A. 2006;103:2075–80.CrossRefPubMedPubMedCentral
89.
Zurück zum Zitat Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, et al. CDD: NCBI’s conserved domain database. Nucleic Acids Res. 2015;43:D222–6.CrossRefPubMed Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, et al. CDD: NCBI’s conserved domain database. Nucleic Acids Res. 2015;43:D222–6.CrossRefPubMed
90.
Zurück zum Zitat Srinivasan VB, Vaidyanathan V, Mondal A, Rajamohan G. Role of the two component signal transduction system CpxAR in conferring cefepime and chloramphenicol resistance in Klebsiella Pneumoniae NTUH-K2044. PLoS One. 2012;7:e33777.CrossRefPubMedPubMedCentral Srinivasan VB, Vaidyanathan V, Mondal A, Rajamohan G. Role of the two component signal transduction system CpxAR in conferring cefepime and chloramphenicol resistance in Klebsiella Pneumoniae NTUH-K2044. PLoS One. 2012;7:e33777.CrossRefPubMedPubMedCentral
91.
Zurück zum Zitat Nawaz M, Sung K, Kweon O, Khan S, Nawaz S, Steele R. Characterisation of novel mutations involved in quinolone resistance in Escherichia Coli isolated from imported shrimp. Int J Antimicrob Agents. 2015;45:471–6.CrossRefPubMed Nawaz M, Sung K, Kweon O, Khan S, Nawaz S, Steele R. Characterisation of novel mutations involved in quinolone resistance in Escherichia Coli isolated from imported shrimp. Int J Antimicrob Agents. 2015;45:471–6.CrossRefPubMed
92.
Zurück zum Zitat Kubanov A, Vorobyev D, Chestkov A, Leinsoo A, Shaskolskiy B, Dementieva E, et al. Molecular epidemiology of drug-resistant Neisseria gonorrhoeae in Russia (current status, 2015). BMC Infect Dis. 2016;16:389.CrossRefPubMedPubMedCentral Kubanov A, Vorobyev D, Chestkov A, Leinsoo A, Shaskolskiy B, Dementieva E, et al. Molecular epidemiology of drug-resistant Neisseria gonorrhoeae in Russia (current status, 2015). BMC Infect Dis. 2016;16:389.CrossRefPubMedPubMedCentral
93.
Zurück zum Zitat Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia Coli rpoB gene that lead to rifampicin resistance. J Mol Biol. 1988;202:45–58.CrossRefPubMed Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia Coli rpoB gene that lead to rifampicin resistance. J Mol Biol. 1988;202:45–58.CrossRefPubMed
94.
Zurück zum Zitat Zhao J, Aoki T. Cloning and nucleotide sequence analysis of a chloramphenicol acetyltransferase gene from vibrio anguillarum. Microbiol Immunol. 1992;36:695–705.CrossRefPubMed Zhao J, Aoki T. Cloning and nucleotide sequence analysis of a chloramphenicol acetyltransferase gene from vibrio anguillarum. Microbiol Immunol. 1992;36:695–705.CrossRefPubMed
95.
Zurück zum Zitat Bay DC, Rommens KL, Turner RJ. Small multidrug resistance proteins: a multidrug transporter family that continues to grow. Biochim Biophys Acta. 2008;1778:1814–38.CrossRefPubMed Bay DC, Rommens KL, Turner RJ. Small multidrug resistance proteins: a multidrug transporter family that continues to grow. Biochim Biophys Acta. 2008;1778:1814–38.CrossRefPubMed
96.
Zurück zum Zitat Lee J-Y, Ko KS. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas Aeruginosa clinical isolates. Diagn Microbiol Infect Dis. 2014;78:271–6.CrossRefPubMed Lee J-Y, Ko KS. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas Aeruginosa clinical isolates. Diagn Microbiol Infect Dis. 2014;78:271–6.CrossRefPubMed
97.
Zurück zum Zitat Franke S, Grass G, Rensing C, Nies DH. Molecular analysis of the copper-transporting efflux system CusCFBA of Escherichia Coli. J Bacteriol. 2003;185:3804–12.CrossRefPubMedPubMedCentral Franke S, Grass G, Rensing C, Nies DH. Molecular analysis of the copper-transporting efflux system CusCFBA of Escherichia Coli. J Bacteriol. 2003;185:3804–12.CrossRefPubMedPubMedCentral
98.
Zurück zum Zitat Nishino K, Nikaido E, Yamaguchi A. Regulation of multidrug efflux systems involved in multidrug and metal resistance of salmonella enterica serovar typhimurium. J Bacteriol. 2007;189:9066–75.CrossRefPubMedPubMedCentral Nishino K, Nikaido E, Yamaguchi A. Regulation of multidrug efflux systems involved in multidrug and metal resistance of salmonella enterica serovar typhimurium. J Bacteriol. 2007;189:9066–75.CrossRefPubMedPubMedCentral
99.
Zurück zum Zitat Outten FW, Huffman DL, Hale JA, O’Halloran TV. The independent cue and cus systems confer copper tolerance during aerobic and anaerobic growth in Escherichia Coli. J Biol Chem. 2001;276:30670–7.CrossRefPubMed Outten FW, Huffman DL, Hale JA, O’Halloran TV. The independent cue and cus systems confer copper tolerance during aerobic and anaerobic growth in Escherichia Coli. J Biol Chem. 2001;276:30670–7.CrossRefPubMed
100.
Zurück zum Zitat Andersson DI. Persistence of antibiotic resistant bacteria. Curr Opin Microbiol. 2003;6:452–6.CrossRefPubMed Andersson DI. Persistence of antibiotic resistant bacteria. Curr Opin Microbiol. 2003;6:452–6.CrossRefPubMed
Metadaten
Titel
Genome sequencing and analysis of the first spontaneous Nanosilver resistant bacterium Proteus mirabilis strain SCDR1
verfasst von
Amr T. M. Saeb
Khalid A. Al-Rubeaan
Mohamed Abouelhoda
Manojkumar Selvaraju
Hamsa T. Tayeb
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
Antimicrobial Resistance & Infection Control / Ausgabe 1/2017
Elektronische ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-017-0277-x

Weitere Artikel der Ausgabe 1/2017

Antimicrobial Resistance & Infection Control 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.